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ABSTRACT 
 
In 2013, 11.4% of births in the United States occurred preterm.1 Due to the immaturity of 
the gastrointestinal tract, these infants are at increased risk of feeding intolerance and necrotizing 
enterocolitis (NEC). NEC is the most common surgical emergency among infants and proves 
fatal for 25-33% those diagnosed.2,3 Effective early detection of these conditions,4 combined 
with targeted therapies to promote intestinal adaptation and weaning from parenteral nutrition 
(PN), represent an important opportunity to improve infant outcomes. To this end, the following 
studies were conducted. 
1. The safety and efficacy of teduglutide, an analog of human glucagon-like peptide-2 
(GLP-2) approved for use only in adults, in reducing PN requirements was assessed via a 
systematic review.5 Fourteen reports met the inclusion criteria. Teduglutide reduced PN 
requirements vs. placebo regardless of PN dependence duration, whereas adverse event 
incidence was similar between groups (number needed to treat to benefit [NNTB] = 3-4; number 
needed to treat to harm [NNTH] = 24-187). 
2. Teduglutide-stimulated intestinal adaptation, potential synergies with partial enteral 
nutrition (PEN), and distinct temporal markers of adaptation were investigated in a neonatal 
piglet model of short bowel syndrome (SBS). Teduglutide improved (P < 0.05) mucosal surface 
area (villus height: duodenum, jejunum, ileum; crypt depth: ileum, colon; proliferation: 
duodenum, jejunum, ileum, colon; apoptosis: jejunum, ileum, colon) and acute nutrient 
processing capacity (glucose: duodenum, jejunum, ileum; glutamine: duodenum, jejunum). PEN 
complimented and synergistically enhanced these effects. Structural adaptation preceded 
functional adaptation, but crypt depth was a strong indicator of adaptation, regardless of time.  
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3. A novel feeding intolerance and NEC risk scoring tool was implemented in the 
University of Illinois-affiliated Carle Foundation Hospital (CFH) level III neonatal intensive care 
unit (NICU). During the study period, 499 tools were completed on the 133 enrolled infants. 
Indices of feeding intolerance included days with emesis, abdominal distention, or gastric 
residuals > 50% of previous feeding volume, and NEC. Anonymous surveys (n = 42) indicated 
nurses’ positive attitudes toward the tool (ease of use of 6.9 [SD 1.9] on 10-point scale). 
Estimated tool completion time was 4.2 minutes (range 1-10). Error rate (9.2%), Cronbach’s 
alpha (0.71), the intraclass correlation coefficient (ICC; 0.99), and Fleiss’ kappa (1.00) were in 
acceptable ranges. Gestational age at birth, hypoxia/asphyxia at birth, red blood cell (RBC) 
transfusion, and congenital heart disease/patent ductus arteriosis (PDA) were significantly 
associated with all four outcome measures. Total optimized tool score was also associated with 
all four outcome measures, with area under the ROC curve (AUC) and diagnostic odds ratio 
(OR) estimates [95% CI] of: emesis, AUC = 0.69 and OR = 1.14 [1.06, 1.23]; abdominal 
distention, AUC = 0.82 and OR = 1.28 [1.18, 1.41]; gastric residuals > 50% of previous feeding 
volume, AUC = 0.64 and OR = 1.11 [1.04, 1.20]; NEC, AUC = 0.90 and OR = 1.29 [1.12, 1.56].  
Scores of infants who did and did not develop each of the four outcome measures were 
significantly (P < 0.05) different, and an “at-risk” threshold of 9 points was established.   
The tool represents a clinically feasible means to discriminate infants at risk of feeding 
intolerance and NEC. Further refinement will improve its clinical utility and identify infants who 
may benefit from targeted therapies, including teduglutide and/or PEN, to promote 
gastrointestinal maturation and improve feeding tolerance.  
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CHAPTER 1 
LITERATURE REVIEW 
 
 
INTRODCTION  
 Worldwide, approximately 15 million infants are born preterm each year.1 The 
combination of gastrointestinal immaturity and high nutrient requirements for catch-up growth 
predispose these infants to feeding intolerance, which may lead to suboptimal nutrition and 
subsequent adverse outcomes including reduced brain growth, cognitive delays, and necrotizing 
enterocolitis (NEC).2-4 Given the large and lasting detrimental impact of feeding intolerance on 
growth and development, it is crucial that this condition be detected as early as possible and 
treated promptly with evidence-based therapies. Targeted investigation into both treatment and 
prevention of feeding intolerance should effectively improve preterm infant outcomes. 
 
PRETERM BIRTH 
 Preterm birth is defined as occurring prior to 37 completed weeks (259 days) gestation.5 
In 2013, 11.4% of births in the United States occurred preterm, representing a 21% increase in 
the overall proportion of preterm births since 1990.6 This increase is largely attributable to higher 
rates of multiple gestations and advancing maternal age.6,7 Eighty percent of preterm births occur 
spontaneously, and only 20% are induced as a result of maternal or fetal distress.8  
Worldwide, the preterm birth rate is 11%, ranging from 5% in parts of Europe to 18% in 
parts of Africa.1 Preterm birth is associated with one-third of all infant deaths in the United 
States, and direct consequences of preterm birth, including lack of feeding support, recently 
became the global leading cause of death of children under 5 years of age.9,10 Survival is 
inversely associated with gestational age at birth, with extremely preterm infants (< 25 weeks 
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completed gestation) having a 50% mortality rate.11,12 Mortality is also inversely associated with 
birth weight. While extremely low birth weight (< 1000 g; ELBW) infants accounted for just 
0.8% of all births in the United States in 2005, they also accounted for 55% of infant deaths the 
same year.12  
 Fortunately, preterm infant survival rates have improved through the use of antenatal 
steroid and surfactant therapies.13-18 However, these surviving infants face severe 
complications,14 with rates of respiratory distress, late onset sepsis, and NEC of 93%, 36%, and 
11%, respectively, in very low birth weight (< 1500 g; VLBW) infants.19 Furthermore, cost of 
care is 10-fold higher in late preterm than term infants, partially due to a 4-fold increase in initial 
hospital length of stay.20 Preterm infants are also twice as likely as their term counterparts to be 
readmitted to the hospital within the first year of life,21 most commonly due to respiratory issues, 
infections, and feeding problems.22-24  
 
 Nutrient needs of the preterm infant 
 Goals for preterm infant feeding are to regain the up to 20% body weight loss 
experienced in the first week of life and achieve postnatal growth comparable to intrauterine 
rates of growth and nutrient accretion.25,26 Enterally or parenterally fed preterm infants require 
120 or 80-100 kcal/kg/day, respectively, and up to 4 g protein/kg/day.27,28 In the event of chronic 
illness, enteral energy needs can increase to up to 150 kcal/kg/day.29,30 Meeting these nutritional 
goals is imperative to achieve desired weight gain up to 2 times that of the term infant,31,32 
improve long-term neurological outcomes, and prevent hospital readmission.33,34 
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Implications of preterm birth for infant feeding 
Parenteral nutrition (PN) administration shortly after birth minimizes weight loss, 
reverses protein catabolism,35-38 reduces mortality, and improves growth and 
neurodevelopmental outcomes.39-41 However, unless contraindicated, enteral nutrition (EN) is 
preferable to PN due its lower costs and avoidance of PN-associated complications, as well as its 
ability to stimulate gastrointestinal maturation and prevent intestinal atrophy. Caution must be 
exercised in providing EN to preterm infants since growth promotion must be balanced by 
concerns of feeding intolerance. Anatomical maturation of the gastrointestinal tract is largely 
complete by 20 weeks gestation, but functional maturation, including motility, gastric acid 
secretion, gastroesophageal sphincter tone, enzyme activity, and bile acid availability, may not 
be complete until term gestation.42-44 Furthermore, cesarean delivery, long neonatal intensive 
care unit (NICU) stay, or antibiotic administration may cause aberrations in intestinal microbial 
colonization which predispose to feeding intolerance and NEC development.45-50  
The signs and symptoms of feeding intolerance are numerous and span from benign 
fussiness and gassiness to potentially serious signs such as bilious gastric residuals, decreased 
gastrointestinal motility, apnea, and bradycardia.  Feeding intolerance is defined as an inability to 
digest enteral feeds due to ineffective or uncoordinated bowel activity51 as evidenced by (1) 
gastric residual volumes greater than 50% of previous feeding volume; (2) abdominal distension 
and/or emesis; and (3) a disruption in the feeding plan (delay, decrease or discontinuation of 
enteral feeds) precipitated by gastrointestinal signs.52 The utility of this definition is limited in 
that it does not provide adequate information for clinicians to distinguish benign transient 
intolerance from early signs of potentially deadly NEC.53 As such, individual interpretation of 
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signs of feeding intolerance can lead to suboptimal nutrition and delayed attainment of full 
enteral feeds due to fear of intolerance exacerbation.  
 
 Prevention of feeding intolerance and necrotizing enterocolitis 
Feeding intolerance prevention strategies are diverse and vary substantially between 
institutions. However, each of the following factors should be carefully considered for preterm 
infant feeding.  
Gastrointestinal priming 
Complete absence of luminal nutrients is associated with marked intestinal mucosal 
atrophy, decreased intestinal size, weight, and enzyme activity, increases in intestinal 
permeability and bacterial translocation, a lack of hormonal response, and delayed motility 
maturation.54,55 Provision of minimal EN, or hypocaloric, trophic feedings < 20 mL/kg/day,56 
reduces intestinal permeability and the risk of late-onset sepsis,57 increases lactase activity,58 
accelerates motility pattern maturation,55 and results in greater cumulative milk intake when 
feedings are advanced.59-61 Trophic feeding does not increase the incidence of NEC, and a recent 
systematic review of 9 randomized controlled trials (1106 infants) determined initial feeding 
beyond the fourth day of life was associated with a longer time to establish full enteral feeds.62,63 
The clinical importance of a few days delay in the establishment of full enteral feeds has not 
been established. Thus the optimal first feed timing remains controversial. 
Feeding substance 
Feeding breast milk rather than formula may speed achievement of full enteral feeds, as 
evidenced by faster achievement of full enteral feeds in VLBW infants fed ≥ 50% human milk 
versus who were exclusively formula-fed.64 Breast milk also offers protection against NEC 
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unmatched by commercial formulas due to its anti-inflammatory, immunomodulatory, and 
prebiotic characteristics as a result of inclusion of immunoglobulins, lactoferrin, 
oligosaccharides, and platelet-activating factor acetylhydrolase.42,62,63,65-67 Each 10% increase in 
enteral intake of human milk is associated with a decrease in NEC risk by a factor of 0.8,68  and a 
recent meta-analysis of randomized controlled trials demonstrated the risk of NEC to be 2.8 
times higher in formula- versus donor milk-fed infants.69 Due to these protective effects against 
NEC, as well as its ability to support structural and functional maturation of the gastrointestinal 
tract,70 breast milk, or donor milk when the mother’s milk is unavailable, should be fed rather 
than formula.  
Energy density of feeds 
In considering energy density of feeds, dilute (10 kcal/oz) versus full-strength (20 
kcal/oz) formula was shown in a systematic review of 3 studies including 102 preterm or low 
birth weight infants to result in earlier attainment of full feeds, lower volume gastric residuals, 
and less abdominal distention.71 The incidence of NEC was not reported in these studies, 
however, and full-strength formula has been shown to promote earlier and more persistent 
intestinal motility compared to 1/3 and 
2/3 dilutions
72 as well as water.73 The limited data in this 
area precludes the ability to make a universal recommendation regarding the optimal energy 
density of feeds for preterm infants.  
Bolus versus continuous feeds 
Bolus feeding mimics the usual fed-fast cycle, results in greater hormonal response than 
continuous infusion, and does not require an infusion pump.74 In contrast, continuous infusion 
increases nutrient absorption by allowing for constant saturation of carrier proteins.75 A 
systematic review of 7 trials which included 511 VLBW infants concluded there was no 
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difference in time to achieve full enteral feeds or regain birth weight, or in NEC rates, in infants 
fed via continuous drip or bolus.76 This lack of effect of feeding mode on time to achieve full 
enteral feeds, combined with the small sample size, make universal recommendation regarding 
the most advantageous feeding mode for preterm infants impossible.  
Rate of volume increase 
A recent systematic review of 6 randomized controlled trials including 618 VLBW 
infants63 suggests no benefit of slow enteral feeding advancement in prevention of feeding 
intolerance, as infants with slow (15-20 mL/kg) advancement took longer to regain birth weight 
and establish full enteral feedings than those receiving more rapid (30-35 mL/kg) feeding 
advancement, and there was no difference in NEC rate between groups. Thus, per the available 
data, advancement of enteral feeds at 30-35 mL/kg appears to be a well-tolerated means to 
promote earlier attainment of full enteral feeds and regain birth weight.  
Non-nutritive suckling 
While non-nutritive suckling does not increase secretion of gastrointestinal hormones, it 
does enhance the transition from tube to oral feeding, promote weight gain, and enhance 
gastrointestinal growth and maturation.77-83 However, non-nutritive suckling does not require the 
level of suck-swallow-breath coordination required for safe oral feeding and thus may not be an 
accurate indicator of an infant’s oral feeding readiness.84 
Medications  
Prokinetic agents such as erythromycin, cisapride, or domperidone may accelerate gastric 
emptying.85,86 However, despite the reduction of time to full enteral feeds with prokinetic 
use,87,88 severe adverse events including fatal cardiac arrhythmia have also been noted.89 
Furthermore, high variability in prokinetic efficacy between trials due to variations in agent, 
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dose, duration of treatment, route of administration (intravenous versus oral), and whether 
administered prophylactically or therapeutically, preclude their widespread use. 90,91 In addition 
to prokinetics, hyperosmolar medications such as multivitamins may induce mucosal injury,92 
and histamine type 2 receptor antagonists may permit bacterial overgrowth due to gastric acid 
suppression, both contributing to development of NEC.93,94 Finally, prolonged antibiotic use, 
especially empirically, may contribute to NEC through alteration of the intestinal microbiota.95,96 
While use of the above or other medications may be necessary during the course of clinical 
treatment in preterm infants, each should be used judiciously and careful attention paid to 
potential adverse effects.  
Probiotics 
Probiotics have been repeatedly shown to decrease the incidence of NEC, likely due to 
improvement of intestinal barrier function, suppression of pathogenic bacteria, and modulation 
of the immune system.97-99 Commonly used strains include Bifidobacterium and Lactobacillus, 
but effects of probiotics are strain-specific and should not be extrapolated to an unlike 
population. Use of caution in the inference of probiotic study results is particularly important in 
neonatal research since as compared to preterm infants, most probiotic research has been 
performed in comparably large/term infants. However, given the promising research in this area, 
one meta-analysis on the use of probiotics in prevention of NEC, including 2176 preterm VLBW 
infants enrolled in 11 randomized controlled trials, concluded that “withholding probiotics from 
high-risk neonates is now almost unethical.”100  
Individual nutrients 
Supplementation of particular nutrients including arginine,101 glutamine,102 medium-
chain triglycerides,103 polyunsaturated fatty acids,104 short chain fatty acids,70 bovine 
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lactoferrin,105 and prebiotics106,107 induce gut maturation and promote enteral tolerance, but none 
of the above are substantiated with adequate data to fully recommend their use for prevention of 
feeding intolerance or NEC.  
Established feeding protocols 
Established feeding protocols, standard orders which take the above factors into account 
and include criteria for discontinuation of feedings, improve infant tolerance and outcomes.108-113 
A meta-analysis of 6 observational studies estimated reductions in NEC risk of up to 87% and 
29% of infants weighing < 2500 g and < 1500 g, respectively, with the use of a feeding 
protocol.114 This risk reduction was hypothesized to be due largely to heightened vigilance and 
increased awareness of NEC rather than specific characteristics of the feedings protocols 
themselves.108,114 Unfortunately, despite best efforts to integrate the above strategies, infants may 
still develop severe feeding intolerance or ultimately, intestinal failure (IF).  
 
PEDIATRIC INTESTINAL FAILURE  
  
Etiology  
 IF, caused by disease, congenital defect, or surgical resection, is characterized by the 
inability to maintain protein, energy, fluid, electrolyte, or micronutrient balance.115 In both adult 
and pediatric patients, the most common etiology of IF is an anatomical reduction in functional 
mass termed short bowel syndrome (SBS).116 SBS is defined by the need for prolonged PN 
following bowel resection, usually for a period of at least three months.117 NEC occurs in 1-3 per 
1000 live births and up to 7.7% of all NICU admissions,118 and is the leading cause (32%) of 
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pediatric SBS. Additional causes include atresia (20%), volvulus (18%), gastroschisis (17%), and 
aganglionosis (6%).119  
 Despite being the largest contributing cause of pediatric SBS and subsequent IF, and 
despite decades of research, the pathogenesis of NEC is still poorly understood, and treatment is 
difficult, resource-intensive, and highly complex.120 Approximately 90% of NEC occurs in 
preterm, rather than term, infants,121,122 with timing of onset inversely related to gestational 
age.123 The current hypothesis regarding pathogenesis is that enteral feeding in the presence of 
pathogenic intestinal colonization induces an excessive inflammatory response within the 
immature intestinal epithelium.124   
 Early detection of NEC and development of effective prevention strategies are 
challenging since the initial clinical manifestations are often nonspecific, involve both systemic 
and gastrointestinal signs,125 and are indistinguishable from isolated feeding intolerance.126 
Seventy percent of infants who develop NEC first experience feeding intolerance,127 but due to 
its nonspecific etiology, NEC often in the advanced stages before diagnosis is made. NEC 
treatment accounts for 19% of all initial newborn health care costs in the United States,128 and 
the average hospital stay for a neonate requiring surgical NEC treatment is 62 days and costs 
nearly $300,000.129 Surgical management to resect necrotic bowel tissue is required in 44-70% 
of diagnosed cases,130-132 and early surgical case mortality is nearly 50%. As such, NEC is the 
most common cause of death in neonates requiring gastrointestinal surgery,133 and among the top 
ten causes of infant mortality in the United States.134 Overall mortality due to NEC ranges from 
15-30%, and is inversely correlated with both gestational age at birth and birth weight.135  
 For neonates, the risk of developing permanent IF following bowel resection is greatest 
when residual bowel length is less than 25% of the predicted length for gestational age.136 
10 
 
However, following resection, term infants with as little as 20 cm of remnant intestine plus an 
intact ileocecal valve, or 40 cm remnant intestine without the ileocecal valve, have successfully 
weaned from PN.137-139 In infants treated with fish oil emulsion at an intestinal rehabilitation 
center, the probability of weaning from PN was 88% and 96% at 12 and 24 months, respectively, 
for infants with ≥ 50cm of small intestine. For infants with < 50 cm of small bowel, the 
probability weaning from PN at 12 and 24 months was 23% and 38%, respectively.140  
 Infant potential for intestinal adaptation following resection far exceeds that of adults,141 
and adaptive potential is greater in preterm than in term infants. This is due to the time course of 
intestinal development, in that the small intestine grows rapidly and doubles in length during the 
last 15 weeks of gestation,142,143 reaching 250-300 cm at term.144 Additional factors that 
determine pediatric prognosis following intestinal resection include anatomic site of resection 
and presence or absence of the ileocecal valve, co-morbidities, and remnant bowel functionality 
and adaptability.145 
 
 Prevalence 
 Estimating the prevalence of pediatric SBS is complicated by variations in diagnosis and 
coding, complex referral and readmission patterns, a paucity of long-term follow-up data, and a 
lack of population-based studies.117,136 However, as medical treatments improve and more infants 
survive SBS, its prevalence is increasing worldwide.146 The National Institute of Child Health 
and Development neonatal research network centers recorded a surgical SBS rate of 0.7% in 
very low birth weight infants born between 2002 and 2005.147 SBS incidence was inversely 
correlated with birth weight in that the incidence in VLBW infants was only half that of ELBW 
infants (28/6,659 or 0.4% versus 61/5,657 or 1.1%, respectively). In Canada, the incidence of 
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SBS in a large tertiary NICU was 22.1 per 1,000 admissions (2.2%), and 24.5 per 100,000 live 
births (0.025%).136 Preterm infants experienced a higher NEC incidence than their term 
counterparts (353.7/100,000 or 0.35% versus 3.5/100,000 or 0.0035% of live births, 
respectively). A study from 7 tertiary neonatal units in Italy revealed 0.1% (26/30,353) of all live 
births and 0.5% (26/5,088) of all patients admitted to the NICU developed IF.148  
 
 Prognosis 
NEC is most commonly diagnosed using Bell’s staging criteria,130 which classifies infants 
as in the stage I suspected, stage II definite, or stage III advanced phases of NEC. Stages I and II 
can be treated medically, but stage III necessitates surgery. A stage II or definite diagnosis 
requires radiographic findings, by which time intestinal damage has already occurred. 
Furthermore, Bell’s criteria are susceptible to inter-observer differences and do not predict the 
severity or course of the disease.149  
 Progress in NEC prevention is impeded by the current inability to predict which infants 
are at highest risk of developing the condition.150 By the time a diagnosis of NEC is confirmed, 
the patient is typically prescribed nil per os (nothing by mouth; NPO) for 5-10 days and is 
administered broad-spectrum antibiotics.151 This lack of enteral nutrients can potentiate intestinal 
atrophy, which in turn hinders the transition to full EN. Thus, as prevention is the key element in 
reducing the burden of NEC,151 there is a need for models capable of stratifying infants 
according to NEC risk to favorably alter disease progression,149 and increase primary prevention 
through judicious short-term feeding interruptions and provision of human milk152,153 and/or 
probiotics.100,154 In the absence of adequate prevention, treatment strategies, which are mainly 
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supportive, include gastric decompression, withholding feedings, and administration of 
antibiotics and fluids.151  
 If surgical resection is required, the resulting SBS progresses through 3 distinct stages, 
including an acute phase, a recovery phase, and a maintenance phase, during which bowel 
adaptation starts as early as 48 hours following resection.155 The acute phase includes the period 
from one to approximately four weeks following resection156 and is characterized by gastric acid 
hypersecretion and large fluid and electrolyte losses. During this phase, treatment with proton 
pump inhibitors or H2 blockers may be necessary to prevent further damage to the intestinal 
epithelium if hypersecretion is severe enough to cause further malabsorption via inactivation of 
pancreatic enzymes or precipitation of bile acid.145 The recovery phase lasts for several months 
and is characterized by gradual improvements in fluid and electrolyte balance.156 Provision of 
EN during this phase should be accompanied by concurrent isoenergetic and isonitrogenous 
weaning from PN.156 Treatment during the final maintenance phase of SBS focuses on 
compensating for any lingering malabsorption through careful diet monitoring and continued PN, 
if necessary.   
 Complications of pediatric SBS commonly include gastric hypersecretion,157,158 bacterial 
overgrowth,159 and sepsis.160 Additional complications include prolonged hospitalization as well 
as growth retardation and developmental delay.161 SBS infants have a disease-specific mortality 
rate nearly 5 times that of infants without SBS (20.2 versus 3.8 per 100 person-years, 
respectively), and compared to SBS-free controls with the same underlying condition, SBS 
infants experience a 3-fold increase in mortality.117,136 SBS-related mortality ranges from 40-
60%,162,163 and is highest during the early post-operative period, after which mortality decreases 
until 200-350 days after surgery, until rising again upon onset of end-stage liver disease.162 
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Hepatic failure accounts for 60% of pediatric SBS mortality,136 which highlights the need for 
optimal PN management as PN is the most significant risk factor for liver disease in SBS infants. 
Infant survival rates are highest when an integrated, multi-disciplinary management and 
treatment approach is used.164  
The first year of pediatric IF treatment is estimated to cost an average of $500,000, and 
subsequent years approximately $300,000. The high initial costs are explained by the need for 
surgical resection as well as its associated complications, and the lengthy initial hospital stay as 
well as frequent early hospital readmissions. The five year cumulative cost of pediatric IF 
treatment is estimated at $1.6 million per patient.165 
 
 Intestinal adaptation following resection  
 Preclinical models 
 In animals, structural adaptations following intestinal resection include increased (1) 
proliferation in both the crypt and epithelium;166-168 (2) crypt depth and villus height;169,170 (3) 
residual intestinal mucosal mass, diameter, and length;169,171-173 (4) intestinal DNA, RNA, and 
protein concentrations;172,174 and (5) angiogenesis and subsequent blood flow.175-177 Functional 
capacities, including expression of transporter proteins such as the sodium/glucose co-transporter 
1 (SGLT1)178,179 and subsequent facilitation of glucose169 as well as lipid absorption,180 are also 
increased in animals following bowel resection. In mice, rats, and pigs, the ileum displays greater 
adaptive potential than does the jejunum.167,175,181,182  
 Humans 
 Human data regarding intestinal adaptation following resection is limited for obvious 
reasons, particularly in infants. However, in adult patients, numerically increased enterocyte 
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hyperplasia and increased villus height were reported 2 years after jejunal-ileal bypass 
surgery,183 and increases in colonic crypt depth and cells per crypt were reported in patients with 
jejunal-colonic anastomosis.184 Furthermore, the human intestine is capable of increasing its 
absorptive capacity through mucosal surface area expansion and enhancement of absorptive 
efficiency per unit surface area.185-188 However, the results of these studies are contradicted by 
others which showed no changes in cellular proliferation, crypt depth, or villus height of SBS 
patients compared to controls.189-191 In neonates, increases in crypt depth and villus height have 
also been observed following bowel resection for NEC.192  
 
 Treatment of intestinal failure 
Parenteral nutrition   
The traditional treatment regimen for pediatric SBS includes PN,193 which in addition to 
providing sufficient energy to promote growth, must also provide adequate protein to avoid 
catabolism. Due to their low nutrient stores and high risk for malnutrition if PN is delayed, PN 
should be initiated as soon as possible in infants with IF, but given the lack of direct data in the 
pediatric population, specific guidelines regarding PN formulation and administration are based 
on adult recommendations and expert opinion.194  While PN can sustain an individual for years, 
it is associated with numerous complications that are especially dangerous to infants including 
intestinal atrophy195,196 and sepsis from intravenous line infections.197 The incidence of PN 
catheter-related infections is estimated at 11-26 infections per 1000 catheter days,198,199 but 
ethanol lock therapy is efficacious in reducing infection rates.200,201 Additionally, 40-60% of 
pediatric patients and up to 85% of neonates that require long-term PN develop intestinal failure-
associated liver disease.202-204 
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 PN fatty acid content requires careful monitoring and prescription, especially with 
prolonged usage. The PN n-6 fatty acid content is of particular concern since these fatty acids are 
precursors to many pro-inflammatory cytokines,205-208 and contribute to the high prevalence of 
liver disease with prolonged PN administration. As such, several n-3 fatty acid-rich lipid 
preparations, including the fish oil emulsion Omegaven,209,210 and the SMOFlipid blend of 
medium chain triglycerides and soybean, olive, and fish oils,211,212 are under investigation for 
both parenteral and enteral use. Early enteral supplementation with Microlipid and fish oil 
reduces intravenous lipid requirements in preterm infants with enterostomy via increased lipid 
absorption213 and intestinal RNA and protein content.214 Recent meta-analysis of the effect of 
fish oil-containing lipid emulsions on prevention or reversal of PN-associated cholestasis in 
neonates (7 trials including 1105 infants) suggested that while effective for reversing PN-
associated cholestasis, these emulsions were ineffective in prevention of the condition.215 Despite 
promising results, these novel lipid formulations remain experimental and require further 
research before widespread use.216  
 As compared to adult IF patients which require adequate PN to maintain fluid and 
electrolyte levels as well as body weight and lean mass composition, pediatric IF patients are 
unique in that they also require additional energy and protein to support growth. Due to the 
complications associated with PN, the goals of pediatric IF treatment are to (1) maintain fluid 
and electrolyte balance; (2) maximize the functional capacity of the remnant intestine; (3) 
promote growth and development; and (4) minimize PN complications and ultimately eliminate 
the need for PN support.119,217 Given that functional adaptations of the intestine can take up to 2 
years,155 IF does not have to be a permanent condition. Rather, complete weaning from PN to EN 
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can be achieved if effective strategies, including surgical, nutritional, and pharmacological 
approaches, are employed to maximize adaptation following resection.   
 Surgical management  
Surgical intervention for NEC is required when necrosis extends through the bowel wall 
and results in perforation. As NEC is the most common cause of pediatric SBS, care must be 
employed during resection of necrotic tissue to conserve as much healthy bowel as possible. 
Following initial resection, various other surgical procedures can be utilized to maximize 
intestinal adaptation. The longitudinal intestinal lengthening and tailoring (LILT) procedure218 
doubles bowel length through longitudinal splitting and subsequent anastomization in series. The 
serial transverse enteroplasty (STEP) procedure219 creates a lengthened, although narrower, 
intestinal lumen through application of surgical staples in a transverse trans-mesenteric fashion. 
In patients with otherwise irreversible IF and liver failure or venous access impairments, 
intestinal transplantation is the final surgical treatment option.  
 Despite increasing intestinal length and/or surface area, each of these procedures is 
technically challenging, and the LILT procedure is specifically recommended against in 
neonates.220 In the absence of surgical intervention following initial bowel resection, an infant 
with 35 cm of remnant small bowel has a 50% probability of being weaned from PN.142 
Encouragingly, over 75% of children undergo some degree of spontaneous intestinal adaptation 
following resection with medical management alone.138,221 For the other 25%, surgery is required 
if intestinal adaptation is to be achieved.  
 Nutritional management  
In combination with PN, hypocaloric trophic EN can be used to stimulate intestinal 
adaptation and promote enteral autonomy. Despite agreement that earlier initiation of feeds 
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promotes intestinal adaptation and minimizes PN-associated complications,159,222 the time of 
initial feeding in IF remains a point of contention. Generally, enteral feedings should be started 
as soon as post-operative ileus resolves.142,163 Initially, continuous, rather than bolus, feeds are 
preferred due to the lower risk of osmotic diarrhea223 and increased absorption and tolerance,75 
but bolus feeds can be advantageous due to their promotion of hormonal stimulation.224  
 The volume and/or concentration of enteral feeds should be increased as adaptation 
progresses, but should not be advanced at a rate that causes stoma/stool output to exceed 40-50 
mL/kg/d.225 Increased output while advancing enteral feeds is typically a result of increased 
osmotic load, and current practice dictates aggressive advancement of enteral feeds to the point 
of, but not beyond, increasing stool output.224 As EN is advanced, PN should be isoenergetically 
and isonitrogenously decreased while carefully monitoring patient ins and outs, including the 
presence of vomiting or diarrhea.145 
 In initiating neonatal EN, breast milk is associated with shorter duration of PN 
dependence as compared with cow’s milk-based or protein hydrolysate formulas,142 likely due to 
the presence of hormones and/or growth factors as well as human milk oligosaccharides. In the 
event where breast milk is not tolerated or is unavailable, a semi-elemental, partially hydrolyzed, 
or amino acid-based formula that contains medium and long chain triglycerides is typically 
used,222,224 although no differences in energy intake, nitrogen balance, or intestinal permeability 
were observed between infants fed hydrolyzed or non-hydrolyzed protein formulas.226  
 Dietary lipids appear to be the most intestinotrophic macronutrient.227,228 However, long 
chain triglycerides require micelle formation for absorption and are not well absorbed in the 
small intestine.229 In contrast, medium chain triglycerides do not require micelle formation for 
absorption and may, therefore, enhance lipid absorption, particularly in the event of cholestasis 
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or bile salt malabsorption. Consequently, a 30:70 medium to long chain triglyceride ratio is 
recommended for SBS patients.230 The incidence of PN-associated liver disease, as well as the 
NPO and PN support durations, are lower in surgical NEC patients when standardized feeding 
guidelines are utilized.231 Thus, similar to prevention of feeding intolerance, use of standardized 
feeding guidelines may be used in conjunction with optimal lipid formations to promote enteral 
autonomy and decrease the incidence of PN-associated liver disease.   
 In addition to optimizing EN lipid content, inclusion of soluble fiber in EN may provide 
short-chain fatty acids (SCFAs) through anaerobic bacterial fermentation. SCFAs are an 
important colonic energy source,232 and decrease fluid loss by stimulating sodium and water 
absorption in the colon.233 SCFAs, and in particular butyrate,234 prevent PN-associated mucosal 
atrophy235 and enhance structural indices of intestinal adaptation236,237 and nutrient transport238 
following resection in rats. Butyrate upregulates glucose transporter 2 (GLUT2) mRNA 
abundance in a Caco2-BBe model of the human intestine, providing insight into the cellular 
mechanism whereby this SCFA upregulates intestinal absorption.239 The volatile nature of 
butyrate precludes its direct inclusion in nutritional formulations. However, provision of 
fermentable substrates such as short-chain fructooligosaccharides, a particularly auspicious 
source of soluble fiber for SBS patients due to their rapid hydrolysis,240 provide a clinically 
feasible means to supply SCFAs. In a neonatal piglet model of SBS in which animals received 
20% of nutrient needs enterally and the reminder parenterally,106 supplementation of PEN with 
short-chain fructooligosaccharides at a level (10 g/L enteral formula) know to produce 
physiologically relevant butyrate concentrations within the distal intestine241,242 augmented both 
structural and functional indices of intestinal adaptation. Based on these data, infants able to 
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tolerate even minimal enteral feeds may benefit from inclusion of soluble fiber if carefully 
selected and dosed to maximize butyrate production through bacterial fermentation.  
 Pharmacological management 
Preclinical results 
Preclinical results demonstrate efficacy of hepatocyte growth factor (HGF) on intestinal 
cell proliferation in culture,243 and on intestinal cell repair, increased mucosal growth, and 
enhanced carbohydrate and protein absorption in rats.244-246 However, no HGF clinical trials have 
been conducted to date. Likewise, epidermal growth factor (EGF) and insulin-like growth factor-
1 (IGF-1) have shown promise in animal studies, but data in humans is lacking.247-249  
 Medications approved for human use 
Pharmacological treatments for IF have historically focused largely on anti-secretory, 
anti-motility, and anti-diarrheal medications. These agents treat the symptoms of IF rather than 
its underlying cause, however, and are ineffective in promotion of intestinal adaptation. 
Furthermore, while widely used in adult IF patients, few, if any, safe and effective 
pharmacological treatments for pediatric SBS-associated IF exist.    
In 2003, the United States Food and Drug Administration (FDA) approved recombinant 
human growth hormone (rHGH; somatropin [Zorbtive], EMD Serono, Rockland, MA) as a 
short-term treatment for adult SBS-IF patients. Animal studies demonstrate enhanced bowel 
growth and ion transport with rHGH treatment250,251 and excised human intestinal tissue displays 
enhanced amino acid transport and intestinal protein content following growth hormone 
treatment.252 FDA approval of rHGH was based on reductions in energy content and frequency 
of PN administration with rHGH compared to placebo.253 When used in conjunction with rHGH, 
glutamine (Nutrestore, Emmaus Medical, Inc., Torrance, CA), a nonessential amino acid that is a 
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primary energy source for enterocytes, is also approved for short-term treatment of SBS.254 
However, despite increases in adult human sodium and protein absorption with this combination 
treatment,255 the widespread use of these 2 therapies has been limited given the frequency of 
treatment-emergent adverse events and the attenuation of therapeutic gains following treatment 
discontinuation.117 Though addition of glutamine to PN prevented atrophy and stimulated 
mucosal hyperplasia in animals following massive small bowel resection,256,257 addition of 
glutamine to PN of ELBW infants in a large multicenter prospective study did not shorten 
duration of PN dependency or increase tolerance to enteral feeds, decrease sepsis or risk of NEC, 
or affect growth.258 Furthermore, a recent meta-analysis (3 trials including 274 infants) 
concluded there was insufficient data to determine if glutamine supplementation could improve 
outcomes, including death or sepsis, of infants with severe gastrointestinal disease.259  
 Glucagon-like peptide-2  
 One promising alternative pharmacologic treatment for IF is provision of exogenous 
glucagon-like peptide-2 (GLP-2). GLP-2 is a 33 amino acid peptide secreted from the 
enteroendocrine L cells of the distal intestine in response to luminal nutrients or intestinal injury. 
GLP-2 is encoded carboxyterminal to glucagon-like peptide-1 (GLP-1) within the proglucagon 
gene, and in mammals, tissue-specific post-translational processing via prohormone convertase 1 
liberates GLP-2 from GLP-1 within the intestine.260 GLP-2 acts through a specific G-protein 
coupled receptor (GLP-2R), which is expressed in both the small and large intestine, as well as in 
the brainstem, lungs, and stomach.261 GLP-2R is localized to enteric neurons,262 subepithelial 
myofibroblasts,261,263 and the intestinal epithelium,264 but has not been identified in crypt cells. 
This localization suggests that downstream effectors such as IGF-1 may be required to elicit the 
intestinotropic effects observed with GLP-2 administration.265  The GLP-2R is highly selective 
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for GLP-2, and exposure to GLP-1 or glucose-dependent insulinotrophic polypeptide, which are 
structurally related to GLP-2, cause only a weak reaction.266  
 Postprandial serum GLP-2 is decreased in patients with extensive small bowel 
resection,267 and serum GLP-2 levels correlate with residual small bowel length in both adults 
and infants.268 Even so, adults with resected ileum but preserved colon display plasma GLP-2 
concentrations significantly elevated over those of healthy control patients.269 Infants with any 
amount of remnant ileum following resection typically fare better than those whose entire ileum 
is resected, and GLP-2 appears to be a factor accounting for this more favorable prognosis.270,271 
Basal levels of GLP-2 secretion are high in preterm infants, suggesting that GLP-2 may also be 
important for inducing bowel growth during the final weeks of gestation.272-274  
 First reported to stimulate enterocyte proliferation in 1996,275 GLP-2 is an 
intestinotrophic mediator capable of increasing absorptive surface area, preventing mucosal 
atrophy, and increasing DNA, RNA and protein concentrations in intestinal cells of animals 
sustained on PN.276-278 In other preclinical models, GLP-2 enhanced nutrient and fluid 
absorption,279 opposed inflammatory insults,280,281 increased intestinal barrier function,282 and 
inhibited gastric emptying and stimulated intestinal blood flow.283-285  
 In adult SBS subjects, GLP-2 increases intestinal absorption and decreases diarrhea,286,287 
and reduces fecal wet weight, energy, nitrogen, sodium, and potassium losses.288 Additionally, 
both intravenous and subcutaneous GLP-2 administration increases mesenteric blood flow in 
healthy adult subjects.284 Despite these promising effects in adults, only limited preclinical data 
is available regarding GLP-2 use in infants.  
In piglets receiving 40 µg/kg/day split into 2 daily doses over a 42-day study period, 
GLP-2 administration had no effect on weight gain, feed intake, or behavior,289 suggesting that 
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administration of exogenous GLP-2 may be safe in growing infants. Villus height, crypt depth, 
and crypt cell proliferation throughout the small intestine and colon were significantly increased, 
while the rate of apoptosis was significantly decreased throughout both the small and large 
intestine in GLP-2- versus vehicle control-treated animals. Overall, pharmacological levels of 
GLP-2 were well tolerated in these piglets, and its tropic effects appear to be confined, as 
desirable, to the gastrointestinal tract. However, these results are contradicted by those of another 
piglet study in which GLP-2 treatment significantly increased cellular proliferation, but 
paradoxically, also led to villus atrophy and a significant decrease in brush border enzyme 
activity compared to control.290 In preterm piglets sustained on total PN following a 50% small 
bowel resection and jejunostomy,291 GLP-2 administration (3.5 µg/kg/hour) increased relative 
wet weight, energy, and macronutrient absorption, and increased sucrase and maltase activities. 
Small intestinal epithelial volume, DNA and protein content, and protein synthetic rate were also 
significantly increased in GLP-2-treated versus control piglets. Currently there is a complete 
dearth of data on the use of GLP-2 for inducing intestinal adaptation in human infants as a 
clinical trial on the safety and dosing of GLP-2 in infants and children with IF was terminated in 
December 2014 due to drug stability concerns.292  
 Teduglutide  
 GLP-2 has clearly demonstrated therapeutic promise for IF treatment. However, the half-
life of GLP-2 is extremely short due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). 
While DPP-IV inhibition modestly potentiates the actions of native GLP-2, it does not result in a 
significant expansion of the mucosal epithelium.293 Therefore, teduglutide (Gattex, NPS 
Pharmaceuticals, Inc., Bedminster, NJ), a DPP-IV-resistant GLP-2 analog which substitutes 
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glycine for alanine in the second N-terminus position, was created which extends the peptide’s 
half-life from 7 minutes to 1.3-2 hours.294,295  
 In adult human trials, teduglutide stimulates mucosal hyperplasia, enhances fluid, 
macronutrient, and electrolyte absorption, increases villus height and crypt depth, and 
significantly reduces PN volume requirements.296-298 In these trials, the adverse event profile of 
teduglutide was similar to placebo and was consistent with underlying disease states.296-303 Based 
on this acceptable benefit to risk ratio, and considering there are only an estimated 3,000 SBS-IF 
patients in the United States eligible for treatment,304 teduglutide was granted orphan drug 
designation and approved by the FDA at a dose of 0.05 mg/kg/day for treatment of PN-
dependent adult patients with SBS in December 2012.305 Teduglutide has also been approved for 
marketing by the European Medicines Agency under the trade name Revestive.304  
No pediatric human trials of teduglutide have yet been completed, but a clinical trial on 
the pharmacodynamics and safety of teduglutide in pediatric SBS subjects is ongoing.306 
However, infants with gastroschisis show a clear positive association between circulating plasma 
GLP-2 concentration and enteral tolerance,307 and infants unable to produce GLP-2 levels of at 
least 15 pM/L with feeds of > 40 kcal/kg died of SBS complications.268 Further research into 
prophylactic or therapeutic teduglutide treatment of preterm infants is warranted given that 
teduglutide may accelerate intestinal maturation and prevent feeding intolerance and NEC. 
Piglets with 50% small intestinal resection and jejunostomy on total PN for 7 days308 
demonstrated a dose-dependent increase in weight per length remnant intestine, and an increased 
intestinal protein fractional synthesis rate with teduglutide (0.2 mg/kg/d) treatment versus 
placebo. However, there were no differences between digestive enzyme activities or 
immunohistochemistry between groups. From this piglet study, it appears that while increasing 
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structural adaptation of the remnant intestine, teduglutide has limited effects on functional 
endpoints.  
 
 Synergistic therapies 
Attempts to maximize intestinal adaptation following resection may be most effective if 
multiple strategies are employed and their synergy can be leveraged. Indeed, several treatment 
combinations including rHGH and glutamine,255 partial EN (PEN) and pre and/or probiotics,106 
EN and GLP-2,309 and GLP-2 plus epidermal growth factor,310 have shown promising results. 
Taking advantage of the different modes and sites of action of these therapies will ensure the best 
possible patient outcomes. Furthermore, the use of a multidisciplinary intestinal rehabilitation 
program, including optimal EN and concurrent PN weaning as well as judicious pharmacological 
and surgical interventions is associated with improved enteral autonomy and survival.311-315  
 
SUMMARY 
 Novel means by which to predict feeding intolerance and prevent its progression to NEC 
and IF are crucial for preterm infants to achieve desired growth rates and enteral autonomy. 
Greater understanding and integration of the disparate factors which impact development of 
feeding intolerance and NEC will contribute to their early detection. Furthermore, development 
of targeted, synergistic treatments for promotion of intestinal maturation in preterm infants at 
high risk of feeding intolerance will advance clinical practice to positively impact both short- and 
long-term outcomes.  
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CHAPTER 2 
RATIONALE AND OBJECTIVES OF RESEARCH 
 
 
RATIONALE 
Preterm infants are at increased risk of feeding intolerance and necrotizing enterocolitis 
(NEC). Despite decades of research, NEC remains a poorly understood disease responsible for 
nearly one-fifth of all initial newborn health care costs in the United States.1 NEC is also the 
most common cause of pediatric IF,2 which necessitates long-term parenteral nutrition (PN) 
unless sufficient intestinal adaptation can be induced to achieve enteral autonomy. Given the 
devastating effects of NEC and complications associated with long-term PN use,3-6 it is crucial 
that NEC be prevented or detected as early as possible, and targeted, evidenced-based therapies 
be applied to infants at high risk of developing NEC. Substantial, cost-effective advancement in 
prevention and early detection of NEC, coupled with targeted prophylactic and therapeutic 
interventions such as partial enteral nutrition (PEN) and teduglutide, will improve patient 
outcomes through heightened awareness and standardized communication of infant NEC risk as 
well as individually tailored care to maximize the quality of life for infants at risk of, or who 
develop, feeding intolerance and NEC. 
 
OBJECTIVES OF RESEARCH 
 The overall objective of this work is to reduce preterm infant morbidity and mortality 
caused by feeding intolerance. The central hypothesis is that accurate prediction of feeding 
intolerance and NEC risk can be achieved and used to identify infants who may benefit from 
targeted therapies to prevent these conditions. Thus, three separate studies were conducted to 
assess (1) the potential of teduglutide as a therapy for pediatric short bowel syndrome (SBS) via 
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systematic review of its safety and efficacy in PN-dependent adults; (2) the efficacy of  
teduglutide, alone or in combination with PEN, for promotion of intestinal adaptation in neonatal 
SBS; and (3) feeding intolerance and NEC risk prediction potential of a novel risk scoring tool to 
identify infants who may benefit from prophylactic or therapeutic teduglutide and/or PEN 
treatment.  
The rationale for these aims is that teduglutide has demonstrated effectiveness in the 
treatment of adults dependent on PN but has not yet been approved for use in pediatrics. 
Furthermore, given the various modes and sites of actions of these therapies, pairing teduglutide 
with PEN may serve to maximally stimulate bowel adaptation. Finally, to date, no validated tools 
exist for the assessment of infant feeding intolerance and NEC risk despite wide recognition that 
early detection will greatly improve patient outcomes.7,8 The following specific aims and 
hypotheses were investigated. 
  
Study 1 
 Specific aims were to assess (1) the efficacy of teduglutide in reducing PN (parenteral 
nutrient and/or fluid) requirements in PN-dependent adults; and (2) the safety of teduglutide in 
this same population.  We hypothesized that following distillation of duplicate and abstract-only 
publications to original results, teduglutide treatment would result in decreased PN requirements 
compared to placebo, and would demonstrate an acceptable safety profile. Chapter 3 
demonstrates that compared to placebo, teduglutide treatment reduces PN requirements in PN-
dependent adults, regardless of PN dependence duration, and that adverse event incidence is 
similar between teduglutide- and placebo-treated groups. Thus, the benefits of teduglutide 
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treatment in this population appear to outweigh the risks, and may improve quality of life 
through additional days off PN.  
  
Study 2 
Specific aims were to (1) assess teduglutide-induced structural and/or functional 
measures of intestinal adaptation in a neonatal piglet model of SBS; (2) evaluate if the effects of 
teduglutide in this model are complimented or synergistically enhanced by provision of PEN; 
and (3) identify distinct temporal markers of adaptation stimulated by these two therapies. We 
hypothesized that teduglutide would enhance structural and functional adaptation of the residual 
small intestine via enhanced mucosal surface area and nutrient processing capacity, and these 
effects would be augmented by the provision of PEN. We further hypothesized that that surface 
area expansion would precede functional adaptation. Chapter 4 demonstrates significant 
improvements in mucosal surface area and acute nutrient processing capacity with teduglutide 
treatment, and that these effects were complimented and synergistically enhanced by PEN in 
both site and timing of action. Additionally, structural markers of adaptation preceded functional 
markers, but crypt depth remained a strong indicator of adaptation, regardless of time. Thus, it 
seems the complimentary and synergistic effects of combination teduglutide and PEN enhance 
intestinal adaptation beyond that of either therapy alone. 
  
Study 3  
 Specific aims were to (1) develop an evidence-based novel tool to assess neonatal feeding 
intolerance and NEC risk; (2) assess the tool’s clinical utility and feasibility of nursing use; and 
(3) validate the tool to achieve sensitive and specific prediction of feeding intolerance and NEC 
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risk. We hypothesized that accurate prediction of infant feeding intolerance and NEC risk could 
be accomplished through comprehensive assessment of feeding practices as well as relevant 
infant and maternal factors, and furthermore, that the tool would be easy to use since similarly 
designed tools have been successful in predicting and reducing the incidence of falls in the 
elderly9 and pressure ulcers in adults.10 Chapter 5 describes the pilot phase of this study, and 
demonstrates the feasibility of implementation of this tool in a neonatal intensive care unit. 
Chapter 6 reinforces pilot phase data, and further, demonstrates tool error rate, consistency, 
discrimination, and predictive ability to be in acceptable ranges. 
  
DISCUSSION 
Chapter 7 summarizes the results of these investigations and future directions for this 
field of research. Emphasis is placed on the potential impact these findings may have on preterm 
infant outcomes, as well as possible future directions for research regarding the risk scoring tool 
to improve its overall clinical utility.  
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CHAPTER 3 
TEDUGLUTIDE FOR SAFE REDUCTION OF PARENTERAL NUTRIENT AND/OR 
FLUID REQUIREMENTS IN ADULTS: A SYSTEMATIC REVIEW1 
 
 
ABSTRACT 
 Background: Teduglutide (Gattex, NPS Pharma, Inc., Bedminster, NJ), a recombinant 
analogue of human glucagon-like peptide-2 (GLP-2), is the first long-term medical therapy 
approved for the treatment of adults dependent on parenteral nutrition (PN). Objective: To assess 
the efficacy and safety of teduglutide in reducing PN (parenteral nutrient and/or fluid) 
requirements in PN-dependent adults. Search Methods: Studies were identified using predefined 
search criteria and multiple databases, including Medline and Embase. The search was 
completed to November 30, 2014 in the absence of date or study design restrictions. Selection 
Criteria: Citation inclusion criteria and methodological quality were assessed by two independent 
reviewers. Outcomes of interest were changes in parenteral nutrient or fluid requirements and 
adverse event incidence. Data Collection and Analysis: From 2693 unique citations, 76 abstracts 
were reviewed. Fourteen reports met the inclusion criteria, including data from 2 phase III, 
double-blind, placebo-controlled clinical trials and their respective extension studies. Data 
extraction was performed by two reviewers using a standardized form. Results: Teduglutide 
reduced PN requirements compared with placebo, whereas adverse event incidence was similar. 
Limitations: Number of subjects studied and the length of follow-up. Conclusions: Teduglutide 
appears to be a safe and well-tolerated means to reduce PN dependence in adults, regardless of 
PN dependence duration.  
___________________________ 
1The final, definitive version of this paper is in press in the Journal of Parenteral and Enteral Nutrition by SAGE 
Publications, Inc. All rights reserved. © 2015 A.S.P.E.N. Naberhuis JK, Tappenden KA. Teduglutide for safe 
reduction of parenteral nutrient and/or fluid requirements in adults: a systematic review. JPEN J Parenter Enteral 
Nutr 2015;e-pub ahead of print.  doi:10.1177/0148607115582063. 
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CLINICAL RELEVANCY STATEMENT 
Patients with intestinal failure (IF) are dependent on parenteral nutrition (PN) for 
nutrients and/or fluid, and prolonged PN-dependence is associated with decreased quality of life 
and numerous complications. Teduglutide is the first long-term pharmacologic treatment 
indicated for adult patients with short bowel syndrome (SBS) who are dependent on parenteral 
support. This systematic review demonstrates that teduglutide is efficacious for minimizing PN 
dependence in adults regardless of PN dependence duration, with a therapeutic gain assessed 
from 32.6 - 39.4% compared to placebo in reducing PN volume requirements by ≥ 20%. 
Furthermore, longer teduglutide treatment duration is associated with increased clinical gains, 
and adverse event incidence on teduglutide is similar to that observed with placebo and is 
consistent with underlying IF.  
 
INTRODUCTION 
 Intestinal failure (IF), caused by disease, congenital defect, or surgical resection, is 
characterized by the inability to maintain protein, energy, fluid, electrolyte, or micronutrient 
balance.1 Parenteral nutrition (PN) is often required in IF in order to maintain body weight as 
well as fluid, nutrient, and electrolyte balance. While life-saving, long term or permanent 
dependence on PN is associated with decreased quality of life1-7 and numerous complications 
including catheter-related bloodstream infections and sepsis, which are the primary cause of 
morbidity and hospital readmission in these patients.8 The risk of PN-related mortality rises with 
increasing PN-dependence duration9 but with proper care, PN complications are rarely lethal10,11 
and the majority of deaths of patients on long-term PN are attributable to the underlying disease 
rather than to the administration of PN.12  
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 The goal of IF treatment is to promote enteral autonomy by maximizing the functional 
capacity of the remnant intestine, which is capable of increasing its absorptive capacity through 
mucosal surface area expansion and enhancement of absorptive efficiency per unit surface 
area.13-16  Capacity for this functional adaptation is maximal in the first 2 years following 
intestinal failure onset,17 and if enteral autonomy is not achieved during this period, the 
likelihood of permanent IF and PN dependence is 95%.18,19 However, enteral autonomy can be 
achieved beyond this initial 2-year period if effective long-term strategies are employed to 
maximize intestinal adaptation following resection.20,21    
 Adaptation of the remnant intestine can be stimulated through a variety of interventions, 
including both dietary and pharmacologic strategies.22 Until recently, pharmacological 
treatments have focused largely on anti-secretory, anti-motility, and anti-diarrheal medications. 
 One promising pharmacologic intervention is the provision of exogenous glucagon-like 
peptide-2 (GLP-2). GLP-2 is a 33 amino acid peptide secreted from the enteroendocrine L cells 
of the distal intestine in response to luminal nutrients. First reported to stimulate enterocyte 
proliferation in 1996,23 GLP-2 has gained widespread support as an intestinotrophic mediator 
capable of increasing absorptive surface area, preventing mucosal atrophy, and increasing DNA, 
RNA and protein concentrations in intestinal cells of animals sustained on PN.24-26 Furthermore, 
GLP-2 enhances nutrient and fluid absorption,27 increases intestinal barrier function,28 and 
inhibits gastric emptying and stimulates intestinal blood flow.29-31 In a proof of concept study, 
GLP-2 increased intestinal wet weight absorption and decreased diarrhea in short bowel 
syndrome (SBS) subjects.32 
 GLP-2 has demonstrated consistent therapeutic promise for IF treatment. However, the 
half-life of GLP-2 is extremely short due to rapid degradation by dipeptidyl peptidase IV. Thus 
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teduglutide, a GLP-2 analog which substitutes glycine for alanine in the second N-terminus 
position, was created which extends the half-life from 7 minutes to 1.3-2 hours.33-35 The US Food 
and Drug Administration (FDA) granted teduglutide orphan drug designation in 2000, and 
approved it for marketing for treatment of PN-dependent adult patients with SBS in December 
2012.35 Teduglutide has also been approved for marketing in Europe under the trade name 
Revestive.36  
 Given the complications and decreased quality of life associated with prolonged PN-
dependence, the potential for duplicate publication bias, and that extension study data is only yet 
available in abstract form which may change substantially or never reach publication, the 
objective of this systematic review is twofold: (1) to distill the available data on teduglutide 
safety and efficacy in reducing PN requirements to original results; and (2) to measure the 
impact of teduglutide via calculation of summary measures including the number needed to treat 
to benefit (NNTB) or harm (NNTH), the odds ratio (OR), and therapeutic gain so that treatment 
decisions can be evidence-based and well-informed, taking into consideration both benefits and 
potential harms of teduglutide treatment.  
 
METHODS 
  This study was conducted according to the procedures outlined by the Cochrane 
Collaboration for systematic reviews37 in order to assess the safety and efficacy of teduglutide in 
reducing PN requirements in PN-dependent adults. A standard protocol for study identification, 
inclusion, and data abstraction was developed and followed after establishment of the following 
study (population, intervention, comparison, and outcome [PICO]) question: “In PN-dependent 
adult humans, would adding teduglutide to standard intestinal rehabilitation therapies safely 
59 
 
result in reduced PN requirements when compared with standard intestinal rehabilitation 
therapies alone?” These standard rehabilitation strategies include individualized treatments based 
on patients’ residual anatomy and SBS status and may include optimization of PN and/or 
conventional medications such as antisecretory agents or antidiarrheals.  
 Multiple databases (Supplementary Table 3.1), clinical trial and adverse event 
registries, and pharmaceutical industry databases were searched from database inception through 
November 30, 2014, in the absence of date or study design restrictions using the following 
search terms: alx-0600, gattex, gly(2)-GLP-2, (gly2)GLP-2, revestive, teduglutide.  Results were 
restricted to English-language studies that enrolled PN-dependent adult humans, and employed 
teduglutide, alone or in combination with additional therapies, to investigate the efficacy and/or 
safety of teduglutide in reducing PN requirements. References from identified citations were 
cross-referenced for completeness. The outcomes of interest were changes in PN requirements 
and adverse event (AE) incidence. No restrictions were applied to the ways in which changes in 
PN requirements were expressed in study results. Hits were assessed for inclusion criteria and 
methodological quality by the two authors, including multiples domains of selection, 
performance, detection, attrition, reporting, and other biases. In the event where a risk of bias 
was unclear, attempts were made to clarify by contacting the senior study authors.  
Methodological quality of studies was graded per the Cochrane Collaboration, and discrepancies 
in trial bias assessments between reviewers were resolved by consensus. A data extraction form 
was developed and piloted jointly by the authors using a representative sample of the studies to 
be reviewed, after which both authors performed data extraction. Qualitative data synthesis, 
rather than meta-analysis, was performed due to variations in length, timing, and dosing 
strategies of the included trials. Summary statistics, including NNTB  (NNTB = 1/[teduglutide 
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responder rate - placebo responder rate], rounded up to the next whole number), NNTH (NNTH 
=  1/[teduglutide event rate - placebo event rate], rounded up to the next whole number), OR (OR 
= [number of teduglutide-treated subjects experiencing event/number of event-free teduglutide 
treated subjects]/[number of placebo-treated subjects experiencing event/number of event-free 
placebo-treated subjects]), and therapeutic gain (teduglutide responder rate - placebo responder 
rate),  were calculated as described by The Cochrane Collaboration37 in order to directly compare 
the safety and clinical efficacy of teduglutide to that of placebo.  
     
RESULTS  
 
Included Studies  
 A total of 2693 citations were identified, and 1402 unique results remained after removal 
of duplicates. Potentially relevant citations were evaluated for inclusion after cross-referencing 
index terms and titles. Seventy-six abstracts were reviewed, after which the remaining 58 full-
text articles and meeting abstracts were assessed for inclusion. Fourteen met the inclusion criteria 
(Figure 3.1). Reasons for article exclusion included duplicate data, review articles or articles that 
provided interim findings when final results were available, use of native rather than analog 
GLP-2, and enrollment of subjects that were not PN-dependent. Five of the included citations are 
full-text articles, and 9 are meeting abstracts. These citations describe three trials as well as their 
respective extension and sub-studies.  Characteristics of included studies, including study 
durations, populations, and outcomes of interest, are found in Table 3.1.  
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Risk of Bias in Included Studies 
 All included studies had a low risk of bias in the following domains: (1) random 
sequence generation (selection bias); (2) incomplete outcome data (attrition bias); (3) selective 
reporting (reporting bias); and (4) other bias (Figure 3.2). Risk of allocation concealment 
(selection) bias in the Gilroy 200838 study, risks of blinding of participants and personnel 
(performance) and blinding of outcome assessment (detection) bias in the Jeppesen 2009 a,39 b,40 
and c41 studies, as well as risks of blinding of outcome assessment (detection bias) in the 
Jeppesen 2014a42 and 2014b,43 Iyer 2014,44 and Fujioka 201445 studies were determined to be 
unclear as these domains were not specifically addressed in these citations. High risk of 
allocation concealment (selection) and blinding of participants and personnel (performance) bias 
were noted in the open-label Jeppesen 2014a,42 2014b,43 Iyer 2014,44 and Fujioka 201445 studies. 
Risk of blinding of outcome assessment (detection) bias was also high in the Gilroy 2008,38 
Compher 2011,46 and Ukleja 201447 studies as the treatments were known by the outcome 
assessors.  
 
Outcomes of Interest  
 Efficacy   
 Responder Rate 
  Table 3.2 shows the proportion of subjects classified as responders across studies, 
achieving ≥ 20% reduction by volume in weekly PN requirements. In Jeppesen 2011,48 response 
rate at 20 and maintained at 24 weeks of treatment was higher (P = 0.005) in teduglutide 0.05 
mg/kg/d (0.05 group) versus placebo subjects (NNTB = 3, OR = 12.63, therapeutic gain = 
39.4%). Response rate of teduglutide 0.10 mg/kg/d (0.10 group) subjects did not differ (P = 
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0.17) from placebo (NNTB = 6, OR = 5.00, therapeutic gain = 18.7%)  Seventeen of 25 (68.4%) 
0.05 subjects and 14 of 27 (52.2%) 0.01 subjects were responders by 52 weeks of treatment.49 As 
compared to week 24, by week 52, 4 of the 24 responders become non-responders, and 11 of 19 
non-responders became responders. Twelve of the 18 subjects who became responders by week 
24 and remained so through week 52 were treated with teduglutide 0.05, and 6 with teduglutide 
0.10.49 Of subjects receiving placebo in the initial study48 but teduglutide in the extension 
study,49 6 of 6 (100.0%) and 2 of 7 (28.6%) responded to teduglutide 0.05 and 0.10, 
respectively.38  
 Similarly, in the Jeppesen 2012 (Study of Teduglutide Effectiveness in Parenteral 
Nutrition-Dependent SBS Subjects [STEPS]) study,50 more (P = 0.002) teduglutide 0.05 versus 
placebo subjects were responders at week 24 (Table 3.2; NNTB = 4, OR = 3.89, therapeutic gain 
= 32.6%). In the extension study in which all subjects received teduglutide 0.05 (STEPS-2),43,45 
subjects previously treated with teduglutide 0.05, placebo, or not randomized achieved responder 
rates of 28 of 30 (93.3%), 16 of 29 (55.2%), and 4 of 6 (66.7%), respectively. Teduglutide 
response was observed regardless of subject characteristics (age, remnant anatomy, baseline PN 
requirements, or disease etiology).43 Importantly, teduglutide efficacy was demonstrated in 
responder rate ORs of > 1 in both phase III trials.48,50  In the Ukleja 2014 study,47 all 6 patients 
(100.0%) experienced > 20% reduction in PN volume while on teduglutide.   
 Changes in PN Volume Requirements 
 Using a strict parenteral weaning algorithm which allowed for reductions in PN volumes 
of ≤ 10% at 4-week intervals, both the teduglutide 0.05 and teduglutide 0.10 groups in the 
Jeppesen 2011 trial48 had reduced PN volume requirements compared to baseline at weeks 8, 12, 
16, 20 and 24 (all P < 0.05). The placebo group also achieved significant reductions at weeks 12 
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and 24 (P = 0.02 and 0.03, respectively). At week 24, both teduglutide dose groups achieved 
mean PN volume requirement reductions of 2.5 L/wk, while the placebo group achieved a 0.91 
L/wk reduction (P = 0.08). At week 24 the teduglutide 0.05, teduglutide 0.10, and placebo 
groups also achieved reductions (P = 0.001, P = 0.03, and P = 0.056, respectively) in parenteral 
energy intake compared to baseline, but reductions in either teduglutide-treated group did not 
differ (P = 0.11) from placebo. By 52 weeks of treatment,49 the teduglutide 0.05 and teduglutide 
0.10 groups decreased their PN volume requirements by 4.9 L/wk (52%) and 3.3 L/wk (26%), 
respectively, compared to baseline. However, 4 weeks after stopping treatment, PN requirements 
of both the teduglutide 0.05 and 0.10 groups increased compared to study end (from 4.0 ± 3.4 to 
5.5 ± 4.4 L/wk, and 8.5 ± 5.1 to 7.9 ± 3.7 L/wk, respectively).  There were no significant changes 
in 7-day urine outputs or oral intakes over the 52-week study period. 
 Subjects with increased (INC) PN requirements by 12 months after stopping teduglutide46 
had a greater (P = 0.04) PN volume reduction while on drug compared to those with stable 
(STABLE) or decreased (DEC) requirements at 12 months off drug (−4.7 versus −1.9 L/wk, 
respectively). INC had increased (P < 0.001) PN requirements at 3, 6, and 12 months off drug 
versus study end while STABLE/DEC requirements did not change. Furthermore, INC PN 
requirements were higher (P = 0.001) than STABLE/DEC (11.9 versus 5.7 L/wk) at 12 months 
off drug. Similar trends were observed in the subset of drug responders, in that INC had 
increased (P < 0.001) PN volume requirements at 3, 6, and 12 months compared to study end 
while STABLE/DEC PN requirements did not change, and INC requirements were greater (P = 
0.003) than those of STABLE/DEC subjects at 12 months off drug. 
 In STEPS, 50 using a weaning algorithm which allowed for 10-30% PN volume 
reductions of baseline PN levels at 4-week intervals, teduglutide 0.05 and placebo subjects 
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achieved mean L/wk reductions in PN volume requirements of 4.4 ± 3.8 (baseline 12.9 ± 7.8) 
and 2.3 ± 2.7 (baseline 13.2 ± 7.4), respectively, after 24 weeks of treatment. The difference in 
absolute change in PN volume requirements between these groups was significant by week 8 (P 
< 0.01) and remained so through week 24 (P < 0.001). Similarly, the difference in percentage 
reduction in PN volume from baseline to week 24 between groups became significant (P < 0.03) 
at week 12 and remained significant (P < 0.03) through week 24. By STEPS50/STEPS-243,45 
treatment, the mean PN volume requirement reduction from baseline was 7.6 (66%), 3.1 (28%), 
and 4.0 (39%) L/wk in the groups treated with teduglutide/teduglutide, placebo/teduglutide, and 
not randomized/teduglutide, respectively. By STEPS50/STEPS-344 treatment, 
teduglutide/teduglutide, placebo/teduglutide, and not-treated/teduglutide subjects reduced their 
PN requirements from baseline by 9.8 (50%), 3.3 (35%), and 5.2 (73%) L/wk, respectively. In 
Ukleja 2014,47 6 of 6 (100.0%) subjects experienced > 20% reduction in PN volume 
requirements from baseline requirements of 1-8 L/wk.   
 PN Infusion Frequency 
 Neither teduglutide-treated group experienced a significant reduction in the number of 
days per week that PN was required in the Jeppesen 201148 trial, but by 52 weeks of treatment,49 
17 of 25 (68%) teduglutide 0.05 and 10 of 27 (37%) teduglutide 0.10 subjects achieved a ≥ 1 
additional d/wk reduction.   
 In STEPS,50 which employed a more aggressive weaning algorithm than the 2011 trial,48 
more (P = 0.005) teduglutide 0.05 than placebo subjects (21 of 39 [54%] versus 9 of 39 [23%], 
respectively) achieved ≥ 1 additional d/wk off of PN by 24 weeks of treatment. In STEPS-2,43,45 
38 of 65 (58.5%) subjects achieved ≥ 1 additional d/wk reduction in PN requirements (by 
STEPS/STEPS-2 treatment: teduglutide/teduglutide, 21/30 [70.0%]; placebo/teduglutide, 14/29 
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[48.3%]; not treated/teduglutide, 3/6 [50.0%]), and 25 of 65 (38.5%) achieved ≥ 3 additional 
d/wk reduction in PN requirements. Of these 25, 18 (72%), 5 (20%), and 2 (8%) were previously 
treated with teduglutide, with placebo, or not randomized, respectively.50 In STEPS-3,44 mean 
weekly PN infusion was reduced by 3.0, 1.7, and 2.8 d/wk in groups with STEPS/STEPS-3 
treatment of teduglutide/teduglutide, placebo/teduglutide, and not treated/teduglutide.  
 Complete Weaning 
 Three subjects completely weaned from PN by 24 weeks of treatment in the Jeppesen 
2011 trial,48 and remained off of PN 12 months later.46 Two of these subjects received 
teduglutide 0.05, and 1 received teduglutide 0.10. By 52 weeks of treatment,49 1 additional 
teduglutide 0.05 subject weaned from PN. 
 In STEPS,50 no subjects were completely weaned from PN by 24 weeks of treatment, but 
in STEPS-2,43,45 13 of 88 (15%) achieved independence from PN, 10 of whom received 
teduglutide in the original randomized controlled trial.50 In STEPS 3,44 2 subjects achieved 
independence from PN after 126 and 130 weeks of teduglutide treatment. In the Ukleja 2014 
study,47 4 of 6 subjects (66.7%) were able to wean from PN.   
 Measures of Intestinal Adaptation 
 In Jeppesen 2011,48 teduglutide 0.05 subjects produced more (P < 0.05) urine at all time 
points versus baseline, despite constant oral fluid intake. Teduglutide 0.10 subjects had increased 
(P = 0.04) urine production at week 4, after which urine production returned to baseline, likely 
due to the reduced (P < 0.05) oral fluid intake at weeks 4, 8, 12, 16, 20, and 24. After 52 weeks 
of treatment,49 fasting plasma citrulline, a biomarker of gut function and mucosal mass,51 
increased 68% (P < 0.001) in teduglutide 0.05 and 86% (P < 0.001) in teduglutide 0.10 subjects 
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compared to baseline. These levels decreased after four weeks off drug by 20% and 32%, 
respectively, but remained higher than at study start.   
 Seventy-two hour balance studies were conducted in a subset of subjects from the 
Jeppesen 2011 study.48 At week 24, the pooled teduglutide groups (n = 11) demonstrated reduced 
fecal energy excretion41 and wet weight39 (P = 0.03 and P = 0.01, respectively), and in those 
whose dietary intake differed < 10% from baseline, intestinal absorption significantly increased 
(P < 0.05) at weeks 8 and 24.41  Teduglutide treatment also decreased fecal sodium (P < 0.001) 
and potassium39 (P = 0.003) excretion, and increased plasma citrulline from baseline to week 24 
(P = 0.001).40 
 In STEPS,50 oral fluid intake of placebo-treated subjects exceeded (P < 0.05) that of 
teduglutide-treated subjects at weeks 12, 20 and 24, and the reduction in fluid composite effect, 
defined as a summation of the increase in urine output (L/wk), reduction in PN/IV volume 
(L/wk), and reduction in oral fluid intake (L/wk), was greater (P ≤ 0.05) in the teduglutide verses 
placebo group at all time points. After 24 weeks of treatment teduglutide, but not placebo, 
increased (P < 0.001) plasma citrulline over baseline.  
 
 Adverse Event Incidence  
 Table 3.3 illustrates the AE, treatment emergent-AE (TE-AE), serious AE (SAE), 
treatment-emergent serious AE (TE-SAE) and drop-out rates of included studies, as well as 
information on laboratory findings, pathology, and death. In Jeppesen 2011,48 79 of 83 (95.2%) 
subjects experienced at least one AE, most commonly abdominal pain, headache, and nausea. 
The most common SAE were catheter-related complications and infections, small intestinal 
obstruction, and fever. Compared to placebo, the AE, SAE, and drop-out rates of both the 
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teduglutide 0.05 (AE, OR = 1.10, NNTH = 187; SAE, OR = 1.30, NNTH = 17; drop-outs, OR = 
3.10, NNTH = 10) and 0.10 groups (AE, OR = 2.07, NNTH = 32; SAE, OR = 1.15, NNTH = 32; 
and drop-outs, OR = 1.00, NNTH = ∞) also demonstrate the relative safety of teduglutide (Table 
3.4). No features of small or large bowel dysplasia were found in these subjects,52 and new 
secondary diagnoses, consistent with underlying disease, were found at a lower frequency in the 
teduglutide groups as compared to placebo (Table 3.3). 
 Similar results were observed in the extension study49 (Table 3.3), in which 50 of 52 
(96.2%) subjects reported at least one TE-AE, most commonly headache, nausea, abdominal 
pain, and nasopharyngitis. Twenty-seven of 52 (51.9%) subjects reported TE-AE related to 
teduglutide, most commonly gastrointestinal disturbance, injection site reactions, and stomal 
hypertrophy. Seven of 52 (13.5%) subjects discontinued from the study because of AE, 4 of 
which, all with a history of Crohn’s disease, were considered treatment-related. Similarly, 27 of 
52 (51.9%) subjects experienced SAE, 5 of which were considered drug-related. One teduglutide 
0.05 and 1 teduglutide 0.10 subject discontinued treatment for reasons unrelated to teduglutide (1 
subject had a hyperplastic colon polyp; 1 had a stroke). By 12 months off drug, 6 of 25 drug 
responders experienced a total of 18 complications, and 4 of 12 non-responders experienced a 
total of 7 complications.46  
 All subjects who received ≥ 1 dose of teduglutide were included in the STEPS50 safety 
analysis. Sixty-nine of 85 (81%) subjects experienced ≥ 1 TE-AE, and similar rates of > 1 TE-
AE, TE-SAE, and drop-outs were observed between the teduglutide 0.05 and placebo groups 
(Table 3.3). Compared to placebo, incidences of ≥ 1 TE-AE (OR = 1.32, NNTH = 24), TE-SAE 
(OR = 1.44, NNTH = 13), and drop-outs due to TE-AE (OR = 0.75, NNTH = 47) of the 
teduglutide 0.05 group demonstrate the safety of teduglutide (Table 3.4). In STEPS-2,43,45 84 of 
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88 (95.5%) subjects experienced TE-AE, most commonly abdominal pain (34%), catheter sepsis 
(28%), and decreased weight (25%). Fifty-six of 88 (63.6%) subjects experienced SAE, but only 
10% were considered treatment-related. These serious AEs included three cases of cancer and 
three deaths. By STEPS50/STEPS-243,45 treatment, 7 of 37 (18.9%) teduglutide/teduglutide and 
16 of 51 placebo+not treated/teduglutide subjects discontinued treatment. No major findings 
were reported in the laboratory values, including liver enzymes, of any included study.42,43,45 All 
subjects experienced TE-AE in STEPS-3,44 but no malignancies or death were reported. No 
subjects discontinued the study because of an AE.  In the Ukleja 2014 study,47 1 (16.7%) subject 
experienced small bowel obstruction, 2 (33.3%) experienced stoma swelling, 1 (16.7%) 
discontinued treatment, and 1 (16.7%) had a teduglutide dose reduction (Table 3.3).   
 
 
DISCUSSION  
 In agreement with the earlier phase II study,53 these collective results demonstrate the 
efficacy of teduglutide in reducing PN requirements in PN-dependent adults. Clinical gains were 
augmented with increased treatment duration, and perhaps most importantly, the reductions in 
infusion frequency experienced by subjects in these trials may potentially have substantial 
implications for employment, activities, sleep, and finances,54 as indicated by the association 
between reductions in PN requirements and significant (P = 0.02) improvements in quality of life 
in STEPS.50,55 The benefits of decreasing PN requirements and allowing subjects the freedom 
and spontaneity that additional days or even hours free from PN offer, cannot be 
underestimated.54 
AE incidence with teduglutide treatment was similar to that observed with placebo, was 
consistent over time and with exogenous GLP-2 administration,56 and furthermore, the most 
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common AE observed were not surprising given that symptoms of abdominal pain, nausea, and 
vomiting also occur with anti-diarrheal treatment in SBS patients. Taken together, these data 
indicate that teduglutide was safe and well tolerated in these trials. However, the included 
randomized trials involved only 172 distinct subjects, who were by definition in stable clinical 
condition with relatively uncomplicated SBS. Thus, additional or more severe AEs may be 
observed once teduglutide is prescribed in a more complex population. 
Subjects included in these phase III clinical trials and their extension studies had been 
dependent on PN for ≥ 12 months prior to initiation of teduglutide treatment, which suggests that 
teduglutide is effective even outside of the initial post-resection window where intestinal 
adaptation would be expected to be maximal. The close monitoring of subjects in each of these 
studies by their respective clinical sites lends credibility to these results, but it is also useful to 
examine effects of teduglutide not specifically addressed by this systematic review in order to 
gain a broader understanding of the effects of teduglutide treatment.   
 Subject body weight was significantly improved in both teduglutide dose groups 
compared to baseline and placebo at various time points in the Jeppesen 2011 study.48 
Encouragingly, these increases were primarily restricted to changes in lean body mass.48,57 Total 
body bone mineral content also increased after 24 weeks of teduglutide treatment, but there were 
no significant changes in bone mineral density. By 12 months off drug,46 median body mass 
index (BMI) was not different for INC versus STABLE/DEC subjects, but INC subjects did have 
significantly lower (P < 0.001) BMI at 3, 6 and 12 months relative to the first off-drug visit, 
while BMI of STABLE/DEC subjects did not change. Similar results were noted in the subset of 
drug responders in that BMI was significantly lower (P < 0.001) in INC subjects at 3, 6 and 12 
months off drug, but did not change in STABLE/DEC subjects. In STEPS,50 teduglutide 0.05 
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subjects experienced a non-significant body weight increase (1.0 ± 3.7 kg; P = 0.10), while 
placebo-treated subjects experienced a non-significant decrease (-0.6 ± 2.8 kg; P = 0.20) in body 
weight. These results demonstrate that teduglutide-stimulated increases in fluid and nutrient 
absorption translate to small but positive changes in body weight.  
 Teduglutide-induced changes in absorption efficiency and body weight can be partially 
explained by changes in intestinal morphology. In the Jeppesen 2011 study,48 both teduglutide 
0.05 and 0.10 subjects experienced significant absolute increases (P = 0.01 and 0.002, 
respectively) from baseline in small intestinal villus height compared to placebo. Teduglutide 
0.10 subjects also had significantly increased (P = 0.02) mean villus surface area in the small 
intestine compared to placebo (teduglutide 0.05, P = 0.08).52 Mean crypt depth of both the large 
and small intestine of the teduglutide 0.10 group was significantly greater (P = 0.02 and P = 
0.01, respectively) than placebo.  
 Overall, these results support the use of teduglutide 0.05 in PN-dependent adults 
regardless of PN dependence duration. However, given that that this systematic review contains 
only 3 relatively small subject populations, it would be valuable to examine the effects of 
teduglutide in a greater number of PN-dependent subjects as well as in subjects with a wider 
variety of gastrointestinal disorders. The studies included in this review also did not measure 
endogenous GLP-2 production, which may explain some of the conflicting results in that 
subjects with L-cells left after resection (those with remnant ileum and/or colon) would have 
higher endogenous GLP-2 production and therefore may be most likely to respond to teduglutide 
administration. In an effort to explain drug potency, it would also be of interest to measure GLP-
2 receptor expression in patients with resection since administration of exogenous GLP-2 
increased ileal GLP-2 receptor expression 3-fold in rats with a 70% jejuno-ileal resection.58 
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Identification of factors that may predict patient response to teduglutide treatment would also be 
valuable given the annual $295,000 per patient cost associated with teduglutide treatment,36 
which is reflective of its orphan indication. Furthermore, the studies included in this review did 
not differentiate between subjects dependent on PN for nutrients versus those dependent on PN 
for fluids/electrolytes only, so it is unknown if teduglutide response varies between these groups. 
Additionally, longer-term follow-up studies are required to assess whether the benefits of 
teduglutide treatment endure following treatment discontinuation, and to directly compare the 
safety and efficacy of teduglutide to that of other approved therapies such as glutamine or 
recombinant growth hormone. Finally, while teduglutide does appear to be safe, it must be noted 
that close monitoring while on the drug is crucial. This is particularly true in (1) patients with 
cardiac issues such as congestive heart failure, due to the increased fluid absorption observed 
with teduglutide treatment; (2) patients with existing tumors since while teduglutide was not 
shown to promote growth of new tumors in the studies included here, animal studies suggest that 
teduglutide may enhance, rather than induce, tumor growth;16,58 and (3) patients on additional 
medications since in addition to enhancing absorption of fluid and nutrients, teduglutide may 
also enhance absorption of other drugs, which is of particular concern for drugs such as digoxin 
which have narrow therapeutic indices.    
 In summary, teduglutide appears to be an efficacious, safe, and well-tolerated means by 
which to reduce PN dependency in adult patients through restoration of intestinal function. High 
bioavailability of subcutaneous teduglutide injections enables convenient once daily 
administration,33,53,59 but careful monitoring of patients on teduglutide will be crucial to ensure 
safety and maximize treatment efficacy. The importance of individualized treatment cannot be 
overstated, and pairing teduglutide with other complementary treatments aimed at enhancing 
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intestinal adaptation may be beneficial. Finally, given promising results in preclinical pediatric 
models,60 despite the current lack of human pediatric GLP-2 and/or teduglutide clinical trials,61 it 
would also be beneficial to investigate the therapeutic effects of teduglutide in pediatric patients 
so the therapeutic benefits of teduglutide could be extended to this population.      
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FIGURES AND TABLES  
 
 
Figure 3.1. Study flow chart.  
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Studya Description Outcomes 
Jeppesen 201148   
Phase III clinical trial. SBS males and females ≥ 18 y on 
PN ≥ 3 d/wk for ≥ 12 mo. Randomized to teduglutide 0.05b 
(n = 35); teduglutide 0.10b (n = 32); or placebo (n = 16) for 
6 mo. 
1. PN volume 
2. Responder ratec 
3. Complete PN weaning 
4. Intestinal adaptation 
5. Safety 
°Jeppesen 2009  
a39, b40, c41 
Subset of Jeppesen 2011 subjects. Teduglutide 0.05 (n = 
10); teduglutide 0.10 (n = 7); or placebo (n = 4) for 6 mo. 
1. Intestinal adaptation 
Tappenden 201352 
Subset of Jeppesen 2011 subjects. Teduglutide 0.05 (n = 
32); teduglutide 0.10 (n = 30); or placebo (n = 15) for 6 mo. 
1. Safety 
O'Keefe 201349 
°Gilroy 200838 
Extension of Jeppesen 2011. Subjects previously on 
teduglutide 0.05 (n = 25) or teduglutide 0.10 (n = 27) 
received 7 additional mo. of same dose. Previously placebo-
treated subjects randomized to teduglutide 0.05 (n = 6) or 
0.10 (n = 7) for 7 mo. 
1. PN infusion frequencyd 
2. Responder rate 
3. Complete PN weaning 
4. Safety 
Compher 201146 
Extension of Jeppesen 2011. Subjects with stable (n = 15) 
or decreased (n = 7) PN requirement by 12 mo. off 
teduglutide compared to those with increased PN 
requirement (n = 15).  
1. PN volume 
2. Complete PN weaning 
3. Safety 
Jeppesen 201250 
(STEPS) 
Phase III clinical trial. SBS males and females ≥ 18 y on 
PN ≥ 3 d/wk for ≥ 12 mo. Previously teduglutide-treated 
subjects not eligible. Subjects randomized to receive 
teduglutide 0.05 (n = 43); or placebo (n = 43) for 6 mo. 
1. PN volume 
2. PN infusion frequency 
3. Responder rate 
4. Safety 
°Jeppesen 2014a42 
°Jeppesen 2014b43 
°Fujioka 201445 
(STEPS-2) 
Open-label extension of STEPS. Treatment in 
STEPS/STEPS2: teduglutide/teduglutide 0.05 (n = 30); 
placebo/teduglutide 0.05 (n = 29); not 
randomized/teduglutide 0.05 (n = 6) for 18-24 mo. 
1. PN volume 
2. PN infusion frequency 
3. Responder rate 
4. Complete PN weaning 
5. Safety 
°Iyer 201444 
(STEPS-3) 
Open-label extension of STEPS/STEPS-2. Teduglutide 0.05 
(n = 14), with STEPS/STEPS-3 treatment of teduglutide/ 
teduglutide (n = 5; treatment duration ≤ 42 mo); placebo/ 
teduglutide (n = 6; treatment duration ≤ 36 mo); not-
treated/teduglutide (n = 3; treatment duration ≤ 36 mo).  
1. PN volume 
2. PN infusion frequency 
3. Complete PN weaning 
4. Safety 
°Ukleja 201447 
Retrospective chart review of SBS patients (n = 6) 
following FDA approval of teduglutide. Teduglutide 0.05 
administered for 1-12 mo. 
1. PN volume 
2. Responder rate 
3. Complete PN weaning 
4. Safety 
a. Parent studies are in grey. Associated/extension studies are directly below each parent study.   
b. mg/kg/d 
c. Responder rate refers to subjects that achieved ≥ 20% volume reduction in PN requirement.  
d. PN infusion frequency expressed as d/wk PN required.  
°Meeting abstract.  
Abbreviations: d, days; FDA, Food and Drug Administration; mo, months; PN, parenteral nutrition; SBS, short 
bowel syndrome; STEPS, study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel 
syndrome subjects; wk, weeks; y, years. 
Table 3.1. Characteristics of included studies. 
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Figure 3.2. Risk of bias assessment. Results of each bias domain are presented as percentages 
across all included studies.   
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Random sequence generation (selection bias) 
Allocation concealment (selection bias) 
Blinding of participants & personnel (performance bias) 
Blinding of outcome assessment (detection bias) 
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias) 
Other bias 
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Studya 
Responder rateb (%) 
Teduglutide  
0.05c 
Teduglutide  
0.10c  
Placebo 
Jeppesen 201148  45.7 25.0 6.3 
   NNTBd; ORe; therapeutic gainf vs. placebo 3; 12.63; 39.4% 6; 5.00; 18.7% - 
O'Keefe 201349 68.4 52.2 - 
Gilroy 200838 100.0 28.6 - 
Jeppesen 201250 (STEPS) 62.8 - 30.2 
   NNTB; OR; therapeutic gain vs. placebo 4; 3.89; 32.6% - - 
Jeppesen 2014b,43 Fujioka 201445 (STEPS-2) 73.8 - - 
Ukleja 201447 100.0 - - 
a. Parent studies are in grey. Associated/extension studies are directly below each parent study.   
b. Responder rate = (number of subjects achieving ≥ 20% volume reduction in PN requirement/total number      
of subjects in group) x 100. 
c. mg/kg/d 
d. NNTB = 1/(teduglutide responder rate - placebo responder rate), rounded up to next whole number. 
e. OR = (number of teduglutide-treated responders/number of teduglutide-treated non-responders)/(number 
placebo-treated responders/number placebo-treated non-responders).  
f. Therapeutic gain = (teduglutide responder rate - placebo responder rate). 
Abbreviations: NNTB, number needed to treat for an additional beneficial outcome; OR, odds ratio; STEPS, 
study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome [SBS] subjects. 
 
Table 3.2. Efficacy of teduglutide: Responder rate.    
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Studya 
Event rateb (%) 
Teduglutide 
0.05c 
Teduglutide 
0.10c 
Placebo 
Jeppesen 201148  
    AE 94.3 96.9 93.8 
    SAE 37.1 34.4 31.3 
    Drop-out 17.1 6.3 6.3 
    Laboratory findingsd NS 
    Death 0.0 
Tappenden 201352 
    Pathology (small & large bowel) e 0.0 0.0 0.0 
    New secondary diagnosisf 12.5 10.0 60.0 
O'Keefe 201349 
    TE-AE 92.0 100.0 - 
    TE-AE related to teduglutide 51.9 - 
    SAE 51.9 - 
    SAE related to teduglutide 9.6 - 
    Drop-out 20.0 14.8 - 
    Pathology (colon only) 0.0 0.0 - 
    Laboratory findings NS - 
    Death 0.0 - 
STEPS: Jeppesen 201250 
    ≥ 1 TE-AE 83.3 - 79.1 
    TE-SAE 35.7 - 27.9 
    Drop-out due to TE-AE 4.8 - 6.9 
    Death 0.0 - 0.0 
    Laboratory findings NS - NS 
STEPS-2: Jeppesen 2014a,42 2014b,43 Fujioka 2014,45  
    TE-AE 95.5 - - 
    SAE 63.6 - - 
    Drop-out 26.1 - - 
    Laboratory findings NS - - 
STEPS-3: Iyer 201444 
    TE-AE 100.0 - - 
    Drop-out due to AE 0.0 - - 
    Malignancy, GI obstruction, death 0.0 - - 
Ukleja 201447 
    Complications 50.0 - - 
    Teduglutide discontinuation 16.7 - - 
    Teduglutide dose reduction 16.7 - - 
a. Parent studies are in grey. Associated/extension studies are directly below each parent study.   
b. Event rate = (number of subjects experiencing event/total number of subjects in group) x 100. 
More than 1 event could occur in a single subject.  
c. mg/kg/day. 
d. Laboratory findings include the following values: vital signs, electrocardiogram, hemoglobin, 
platelets, differential white blood cells, urea, electrolytes, liver function tests, and C-reactive 
protein.  
e. Pathology refers to dysplastic transformation, including adenomatous polyps.  
f. New secondary diagnoses include colitis (ulcerative, acute non-specific, collagenous, 
eosinophilic, lymphocytic), Crohn's disease, non-specific increased mucosal inflammation, 
sarcoidosis, or villus abnormality (decreased villus height and/or volume).  
Abbreviations: AE, adverse event; GI, gastrointestinal; NS, not significant; SAE, serious adverse 
event; STEPS, study of teduglutide effectiveness in parenteral nutrition-dependent short bowel 
syndrome [SBS] subjects; TE-AE, treatment-emergent adverse event; TE-SAE, treatment-
emergent serious adverse event. 
 
Table 3.3. Safety of teduglutide: Adverse event incidence.   
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Study 
Teduglutide 0.05a  
vs. placebo 
Teduglutide 0.10a   
vs. placebo 
NNTHb ORc NNTH OR 
Jeppesen 201148 
     AE 187 1.10 32 2.07 
     SAE 17 1.30 32 1.15 
     Drop-outs 10 3.10 ∞ 1.00 
STEPS: Jeppesen 201250 
     ≥ 1 TE-AE 24 1.32 - - 
     TE-SAE 13 1.44 - - 
     Drop-outs 47 0.75 - - 
a. mg/kg/day.  
b. NNTH = 1/(teduglutide event rate - placebo event rate), rounded up to next whole 
number. 
c. OR = (number of teduglutide-treated subjects experiencing event/number of 
event-free teduglutide treated subjects)/(number of placebo-treated subjects 
experiencing event/number of event-free placebo-treated subjects). 
Abbreviations: AE, adverse event; NNTH, number needed to treat for one additional 
harmful outcome; OR, odds ratio SAE, serious adverse event; STEPS, study of 
teduglutide effectiveness in parenteral nutrition-dependent short bowel syndrome 
[SBS] subjects; TE-AE, treatment-emergent adverse event; TE-SAE, treatment-
emergent serious adverse event. 
 
Table 3.4. Safety of teduglutide: Number needed to treat to harm and adverse event odds ratio.  
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General and Subject Specific Databases 
Academic OneFile 
AgeLine 
BiblioMap 
BIOSIS Previews 
Cochrane Central Register of Controlled Trials  
Cochrane Database of Abstracts of Reviews of Effects 
Cumulative Index to Nursing and Allied Health  
Database of Promoting Health Effectiveness Reviews  
Derwent Drug File 
Embase 
EMCare 
Google Scholar 
HighWire Press 
MEDLINE 
National Guidelines Clearinghouse 
National Library of Medicine 
OTseeker 
Physiotherapy Evidence Database 
POPLINE 
Scopus 
The Trials Register of Promoting Health Interventions 
Turning Research Into Practice 
Web of Science 
Grey Literature Databases 
Trial Registries 
AstraZeneca Clinical Trials Registry 
Bristol-Myers Squibb Clinical Trial Registry 
CenterWatch Clinical Trials Listing Service 
Clinical Research Network Portfolio Database (UK) 
Clinical Trials Gateway/National Research Register (UK)  
Clinicaltrialresults.org 
Clinicaltrials.gov 
Community Research & Development Information Service (European Union) 
Current Controlled Trials metaRegister of Controlled Trials (including archives) 
Eli Lilly and Company Clinical Trial Registry 
European Medicines Agency  
Food and Drug Administration  
GlaxoSmithKline Clinical Trial Registry 
International Standard Randomized Controlled Trial Number Register 
Novartis Clinical Trial Registry 
Pfizer (Wyeth) Clinical Trial Listings 
Roche Clinical Trial Protocol Registry 
South African National Clinical Trial Register 
The Association of the British Pharmaceutical Industry 
World Health Organization International Clinical Trials Registry 
Conference Proceedings and Dissertations 
British Library Direct Plus 
DissOnline (Germany)  
Index to Theses in Great Britain and Ireland 
International Federation of Pharmaceutical Manufacturers and Associations 
International Pharmaceutical Abstracts 
ISI Proceedings 
King’s Fund 
National Technical Information Service 
New York Academy of Medicine Grey Literature Database 
OAlster 
ProQuest Dissertations and Theses 
System for Information of Grey Literature in Europe 
Regional Databases 
Index Medicus (African, Eastern Mediterranean, South-East Asian, Western Pacific) 
IndMED (India) 
Informit Medical Database (Australia) 
KoreaMed 
Latin American and Caribbean Health Sciences Literature  
Economic Databases 
Cost Effectiveness Analysis Registry (Tufts Medical Center) 
EconLit (American Economic Association) 
European Network of Health Economic Evaluation 
National Health Service Economic Evaluation (UK) 
Adverse Event Databases 
Regulatory Agency Safety Bulletins 
Current Problems in Pharmacovigilence (UK) 
Australian Adverse Drug Reactions Bulletin/Australian Register of Therapeutic Goods 
European Public Assessment Reports from the European Medicines Evaluation Agency 
Food and Drug Administration (FDA) Medwatch and Drugs@FDA 
Other Databases 
Iowa Drug Information Service 
Medicines Transparency Alliance 
Toxicology Literature Online 
 
Supplementary Table 3.1. Full list of databases searched.  
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CHAPTER 4 
TEDUGLUTIDE-STIMULATED INTESTINAL ADAPTATION IS COMPLIMENTED 
AND SYNERGISTICALLY ENHANCED BY PARTIAL ENTERAL NUTRITION IN A 
NEONATAL PIGLET MODEL OF SHORT BOWEL SYNDROME 
 
ABSTRACT  
Background: Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, is available for 
long-term use by parenteral nutrition- (PN) dependent adults to promote intestinal adaptation, but 
is not approved for use in pediatric patients. Objectives: Assess teduglutide-stimulated induced 
intestinal adaptation, potential synergies with partial enteral nutrition (PEN), and distinct 
temporal markers of adaptation in a neonatal piglet model of short bowel syndrome (SBS). 
Materials and methods: Neonatal piglets (48 hours old; n = 72) underwent an 80% jejuno-ileal 
resection and were randomized to 1 of 4 treatment groups, in a 2x2 factorial design, with total 
parenteral nutrition (TPN) or PEN (80% standard PN/20% standard enteral nutrition) and 
teduglutide (0.10 mg/kg/d) or control. Piglets received infusions for 4 hr, 48 hr, or 7 d. Results: 
Teduglutide improved (P < 0.05) mucosal surface area (villus height: duodenum, jejunum, 
ileum; crypt depth: ileum, colon; proliferation: duodenum, jejunum, ileum; colon; apoptosis: 
jejunum, ileum, colon) and acute nutrient processing capacity (glucose: duodenum, jejunum, 
ileum; glutamine: duodenum, jejunum). These effects were complimented and synergistically 
enhanced by PEN in both site and timing of action. Structural adaptations preceded functional 
adaptations, but crypt depth remained a strong indicator of adaptation, regardless of time. 
Conclusions: The combination of teduglutide and PEN enhance intestinal adaptation beyond that 
of either therapy alone.  
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CLINICAL RELEVANCY STATEMENT  
 Patients dependent on parenteral nutrition (PN) are most likely to achieve enteral 
autonomy if strategic post-operative therapies aimed at maximizing intestinal adaptation are 
employed. Teduglutide has been shown to effectively stimulate intestinal adaptation and promote 
weaning from PN in both preclinical and adult human trials, but is not approved for use in the 
pediatric population. The data presented here demonstrate that teduglutide increases structural, 
and transiently increases functional, measures of intestinal adaptation in a neonatal piglet model 
of short bowel syndrome (SBS), and furthermore, these adaptations are complimented and 
synergistically augmented by provision of partial enteral nutrition (PEN).  
 
INTRODUCTION 
Short bowel syndrome (SBS) is a malabsorptive state occurring as a result of reduced 
functional bowel length.1,2 In infants, SBS results in inadequate intestinal surface area for 
digestion and absorption of sufficient enteral nutrients to support growth and development.1 SBS 
is one of the most lethal conditions in infancy and childhood,2 and accounts for 1.4% of all 
deaths of children under 4 years of age.3 Necrotizing enterocolitis (NEC) is the principal cause of 
pediatric SBS, responsible for 32% of cases.4 Preterm infants, which comprised 11.4% of births 
in the United States in 2013,5 are especially vulnerable to developing NEC due to the immaturity 
of the gastrointestinal tract. SBS is particularly devastating in this population since infants who 
require parenteral nutrition (PN) secondary to intestinal failure following bowel resection require 
adequate nutrients not only to maintain fluid and electrolyte levels, body weight, and lean mass 
composition as adults do, but also require additional energy and protein to support growth.6 
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PN should be initiated as soon as possible in infants with SBS to reduce the risk of 
malnutrition precipitated by low nutrient stores.7 However, prolonged PN usage is associated 
with numerous complications including intestinal atrophy,8,9 liver damage,10 and sepsis from 
intravenous line infections.2 Consequently, in addition to promoting growth and development in 
pediatric patients,11 one of the primary goals of SBS treatment is  to maximize the functional 
capacity of the remnant intestine and ultimately eliminate the need for PN support.4  
Provision of partial enteral nutrition (PEN) maintains intestinal structural and functional 
integrity12,13 and augments bowel adaptation following resection.6,14-18 Luminal nutrients are the 
primary stimulus for this adaptation,19,20 as well as for the release of humoral factors including 
glucagon-like peptide-2 (GLP-2). GLP-2 is important for inducing bowel growth during the final 
weeks of gestation,21-23 and serum GLP-2 levels correlate with residual small bowel length in 
both adults and infants.24 Provision of exogenous GLP-2 induces numerous indices of intestinal 
adaptation in preclinical models,25-37 including improved enteral tolerance and a reduction in the 
number of days per week PN is required.37 Furthermore, while GLP-2 and PEN synergistically 
stimulate intestinal adaptation in adult rat models of SBS,38,39 the efficacy of this combination 
therapy has yet to be investigated in a pediatric model of SBS.    
GLP-2 has clearly demonstrated therapeutic promise for SBS treatment, but the half-life 
of GLP-2 is extremely short due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). 
Therefore, teduglutide (Gattex, NPS Pharmaceuticals, Inc., Bedminster, NJ), a DPP-IV-resistant 
GLP-2 analog, was created which extends the peptide’s half-life from 7 minutes to 1.3-2 
hours.40-42 Based on reductions in PN requirements as well as an adverse event profile similar to 
placebo and consistent with underlying disease states, teduglutide has been approved for long-
term treatment of adults with SBS intestinal failure in both the United States and Europe, but no 
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human pediatric GLP-2 and/or teduglutide safety and efficacy studies have yet been completed.18 
Teduglutide treatment in TPN-fed piglets with 50% small bowel resection improved structural, 
but not functional, measures of adaptation.43  
 Given the immense human suffering and healthcare burden associated with pediatric 
SBS, development of novel synergistic medical nutrition therapies aimed at intestinal 
rehabilitation is critical. The objective of this work was to explore the efficacy of teduglutide, 
alone or in combination with PEN, for enhancing intestinal adaptation in a well-
characterized14,44-47 neonatal piglet model of SBS. Our focus was on three particular questions:  
1. Does teduglutide induce structural and/or functional measures of intestinal adaptation 
in a neonatal piglet model of SBS? 
2. Are the effects of teduglutide in this model complimented or synergistically enhanced 
by the provision of PEN? 
3. Can distinct temporal markers of adaptation stimulated by these two therapies be 
identified?  
We hypothesized that teduglutide would enhance structural and functional adaptation of 
the residual small intestine via enhanced mucosal surface area and nutrient processing capacity, 
and that these effects would be augmented by the provision of PEN. Furthermore, we 
hypothesized that surface area expansion would precede functional adaptation. 
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METHODS 
 
Experimental design 
 Neonatal piglets (n = 72; Duroc x Landrace cross) were obtained from a University of 
Illinois Urbana-Champaign swine producer within 48 hours of birth and underwent placement of 
a jugular catheter and an 80% proximal jejuno-ileal resection, as previously described.47 
Littermate piglets were randomly assigned to 1 of 4 treatment groups: 
 1. 100% PN with vehicle control (TPN-); 
 2. 80% PN and 20% enteral nutrition with vehicle control (PEN-); 
 3. 100% PN with teduglutide (0.10 mg/kg/d; TPN+), or; 
 4. 80% PN and 20% enteral nutrition with teduglutide (0.10 mg/kg/d; PEN+). 
 Within each treatment group, animals were further randomized to receive infusions for 
various time points following surgery to allow for examination of acute (4- and 48-hour) and 
chronic (7-day) adaptations.  All animal procedures were approved by the Illinois Institutional 
Animal Care and Use Committee at the University of Illinois at Urbana-Champaign. 
  
Animal care and housing 
 Vital signs and activity levels were monitored in each piglet during recovery from 
surgery. Buprenex analgesic (0.01 mg/kg; Reckitt Benckiser Pharmaceuticals, Richmond, VA) 
and Naxcel broad spectrum antibiotic (3.0 mg/kg; Pharmacia & UpJohn Company, Inc., 
Kalamazoo, MI) were provided intravenously immediately after surgery and for the following 48 
hours to minimize pain and decrease postoperative infection.  Piglets were individually housed in 
metabolic cages as previously described.47 A full clinical assessment, including the following 
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criteria, was performed each morning:  body temperature, weight gain, activity level, healing of 
surgical site, and absence of edema and guarded posture. A partial clinical assessment was 
performed each evening to reevaluate piglet condition. 
 
Nutrient solutions and administration 
 Nutrition was provided to piglets in amounts necessary to meet daily requirements of 253 
kcal/kg/d and 12.8 g protein/kg/d, as determined by the National Research Council.48 PN was 
formulated and compounded daily, as previously described,47 and was continuously infused via a 
Flo-Gard 6200 volumetric infusion pump (Travenol Laboratories, Deerfield IL). The PN solution 
provided 253 kcal/kg/d and 12.8 g amino acids/kg/d to TPN piglets, and 202 kcal/kg/d and 10.24 
g amino acids/kg/d to PEN piglets. Infused volumes were quantified and recorded daily.  
 Polymeric pig milk replacer formula (Animix LLC, Juneau, WI) was freshly 
reconstituted each morning to a concentration of 2.7 kcal/mL. Piglets receiving PEN were 
provided 20% of their daily nutritional needs via oral gavage delivered in 2 separate boluses, 
with 60 mL delivered in the morning, and the residual volume provided in the evening. PN 
infusion was stopped 2 hours before euthanasia, at which time PEN piglets received 60 mL of 
formula.     
 
Teduglutide composition and administration 
 Teduglutide ([Gly2]GLP-2, Gattex, NPS Pharmaceuticals, Bedminster, NJ) was 
aseptically diluted into vehicle buffer (35 mM dibasic sodium phosphate, 50 mM D-histidine, 
3% wt/vol D-mannitol) and administered intravenously every 12 hours for a total dose of 0.10 
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mg/kg/d. Vehicle control animals received a weight-calculated equivalent volume of vehicle 
buffer. 
 
Sample collection 
 Piglets were euthanized via intravenous delivery of 0.39 g/mL sodium pentobarbital 
(Fatal Plus; Vortech Pharmaceuticals, Ltd., Chicago, IL). Blood samples were collected via 
cardiac puncture as previously described,47 and plasma was stored at -80°C until further use. The 
gastrointestinal tract was quickly excised, and samples for assessment of both structural and 
functional adaptations were processed as previously described.47 The weight of the visceral 
organs (heart, liver, kidneys, pancreas, stomach, spleen) and eviscerated carcass were also 
recorded. 
 
Intestinal tissue composition  
 DNA and protein concentrations of all intestinal segments were determined by the 
Hoechst49 and Bradford50 methods, respectively, as previously described.14  
 
Gross histomorphology 
 Intestinal length, weight, and mucosal dry weight were quantified and recorded. Intestinal 
segment lengths were normalized to body weight (cm/kg) and intestinal wet weights were 
assessed per unit length (g/cm). Mucosal and non-mucosal dry weights were normalized to unit 
sample length (mg/cm) and expressed as a percentage of mucosa to total mucosal weight. 
Percentage mucosa was calculated as (mg mucosa) / (mg mucosa + mg non-mucosa) x 100.  
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 Morphometric analysis of mucosal architecture was completed as previously described.47 
Sections were visualized at 5x magnification on a Zeiss Axioskop (Model 40, Zeiss, Thornwood, 
NY) with an AxioCam MRc5 and analyzed using the AxioVision software package (Version 4.5, 
Zeiss). Villus height and crypt depth were measured in 8-10 intact, well-oriented villi and crypts 
within each sample.  
 
Epithelial cell proliferation 
 Epithelial cell proliferation was assessed by immunohistochemical staining for 
proliferating cell nuclear antigen (PCNA) as previously described.14 Antigen retrieval was 
performed by placing slides in a 95°C citrate buffer (10 mM citric acid, 0.05% Tween-20, pH 
6.0; Sigma-Aldrich) bath for 10 minutes for small intestinal segments, and 15 minutes for colon 
segments. Endogenous peroxidase was quenched for 10 minutes with a 3.0% peroxide solution, 
and samples were incubated with 2% normal horse serum (NHS) for 20 minutes to prevent 
nonspecific binding. Primary PCNA antibody was diluted 1:1000 in 1% NHS phosphate buffered 
saline. Nanozoomer Slide Scanner Digital Pathology System and NDP View imaging software 
were used to capture images at 20× magnification. Within each sample, PCNA-positive cells in 
8-10 intact, well-oriented crypts were counted using ImageJ (National Institutes of Health, 
Bethesda, MD). 
 
Epithelial cell apoptosis 
 DNA fragmentation was measured immunohistochemically as previously described14 
with the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (terminal deoxynucleotidyl 
transferase dUTP nick end labeling [TUNEL] assay; Millipore) to assess jejunal, ileal, and 
94 
 
colonic epithelial cell apoptosis. Nanozoomer Slide Scanner Digital Pathology System and NDP 
View imaging software were used to capture images at 20× magnification. TUNEL-positive cells 
in 8-10 intact, well-oriented crypts of each sample were counted using ImageJ (National 
Institutes of Health, Bethesda, MD). 
 
Epithelial cell differentiation 
 As previously described,14 real-time reverse transcription polymerase chain reaction was 
used to quantify jejunal, ileal, and colonic Cdx2 mRNA abundance, a marker of intestinal 
cellular differentiation. Cdx2 and endogenous 18S controls were measured in separate wells with 
a TaqMan ABI 9700. Samples were quantified using the ABI Sequence Detection System 
software and a pooled cDNA standard curve, and were normalized to 18S expression. 
 
Mucosal ion and nutrient transport 
 Mucosal ion and nutrient transport were measured using modified Ussing chambers 
(Physiologic Instruments, San Diego, CA) as described previously.14 Dual-channel 
voltage/current clamps (VCC MC2, Physiologic Instruments, San Diego, CA) with a computer 
interface allowed for real-time data acquisition and analysis (Acquire & Analyze, Physiologic 
Instruments). 
 
Statistics 
 Statistical analyses were performed using the SAS (Version 9.4, SAS Institute Inc., Cary, 
NC) mixed model procedure. A log, square-root, or reciprocal transformation of the residuals 
was performed if data were determined to be non-normal by the univariate procedure.  
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Comparisons included (1) drug (teduglutide versus vehicle; pooling route of nutrient 
administration [PEN and TPN]), and interactions with time (4 hours versus 48 hours vs 7 days); 
and (2) route of nutrient administration (PEN versus TPN) and interactions with drug 
(teduglutide versus vehicle) and/or time (4 hours versus 48 hours vs 7 days). Means were 
separated using the least significant difference when a main effect of drug or route of nutrient 
administration existed in the absence of significant interactions. Litter was included as a random 
effect. Each intestinal segment was analyzed separately from the others, and differences within 
time points were assessed individually. Statistical significance was defined as P < 0.05.   
 Principal component analysis (PCA) was completed on data derived from all treatment 
groups at 4 hours (PCA 1; n = 24), 48 hours (PCA 2; n = 23), and 7 days (PCA 3; n = 24), as 
well as on the entire pooled group (PCA 4; n = 71) as outlined by Jolliffe.51 All PCAs initially 
included 81 variables. The primary objective was to investigate the temporal sequence of 
teduglutide- and/or PEN-mediated intestinal adaptation following massive small bowel resection, 
and to identify distinct markers of adaptation over time. In PCAs 1-3, 80% of the total variance 
was accounted for by 10 factors; therefore, 10 factors were retained in the final analysis. For 
PCA 4, 18 factors were retained in order to explain 80% of the variance. Variables that did not 
load on any factor retained (correlation coefficient between variables and factors │r│≤ 0.5) were 
excluded from the final analyses. When several variables were significantly correlated (│r│> 
0.6, P < 0.05) within a group of similar variables, only the variables with the highest factor 
loadings were retained for the final analyses. PCA was performed using JMP (Version 11; SAS 
Institute, Cary, NC). 
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RESULTS 
 
Growth and nutrition support 
 A total of 72 surgeries were performed with 71 piglets completing the study. One piglet 
died of surgical complications. Piglet body weight did not differ between treatments at any point 
during the study.  All piglets received adequate nutrients via TPN or PEN to provide satisfactory 
growth and meet nutritional needs, and all groups gained weight over time following initial post-
surgical weight loss at 4 hours. Daily weight gain was not affected by treatment, and weight of 
the heart, kidney, and pancreas, normalized to body weight (g/kg), did not differ among 
treatments at any time (data not shown). Stomach weight was not different between groups at 4 
hours, but decreased (4 hours = 7.55 ± 0.46, 48 hours = 7.34 ± 0.75, and 7 days = 5.83 ± 0.23 
g/kg body weight; P = 0.03) over time in TPN vehicle control (TPN-) animals. Spleen weight 
increased over time (4 hours = 1.73 ± 0.27, 48 hours = 1.89 ± 0.22, 7 days = 3.07 ± 0.37 g/kg 
body weight; P < 0.001), regardless of treatment. Liver weight increased (4 hours = 37.77 ± 
2.45, 48 hours = 42.76 ± 3.96, 7 days = 33.57 ± 1.53 g/kg body weight; P < 0.001) from 4 to 48 
hours, but returned to 4 hour values by 7 days, regardless of treatment.  
 
Question 1: Does teduglutide induce structural and/or functional measures of 
intestinal adaptation in a neonatal piglet model of SBS? 
Structural adaptations 
Gross intestinal morphology 
Teduglutide increased colonic wet weight (teduglutide = 0.401 ± 0.058 versus vehicle = 
0.274 ± 0.020 g/cm; P = 0.02) and ileal mucosal mass (teduglutide = 55.8  3.20 versus vehicle 
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= 47.2  2.69% mucosa; P = 0.04), with a trend for increased duodenal length (P = 0.056) 
regardless of route of nutrient administration or time. Teduglutide did not affect wet weight, 
mucosal mass, or length of any other intestinal segments (data not shown).  
Intestinal tissue composition 
Intestinal DNA concentration (µg DNA/mg mucosa), a marker of cellularity used to 
assess compositional changes associated with growth, was not affected by teduglutide 
administration in any intestinal segment (data not shown). Teduglutide administration also did 
not affect protein concentration or protein/DNA concentration of any intestinal segment (data not 
shown).  
Crypt-villus architecture  
Teduglutide increased villus height by 20% in the duodenum (P = 0.005) and jejunum (P 
= 0.002), and by 12% in the ileum (P = 0.03), regardless of time or route of nutrient 
administration (Figure 4.1). Similarly, teduglutide increased ileal (P < 0.001) and colonic (P = 
0.006) crypt depth versus vehicle, regardless of time or route of nutrition administration (Figure 
4.2). 
Epithelial cell turnover 
 Epithelial cell proliferation was increased by teduglutide in all intestinal segments, 
regardless of route of nutrient administration or time (duodenum, jejunum, ileum all P < 0.001; 
colon, P = 0.008; Figure 4.3A). Teduglutide treatment also decreased apoptosis (TUNEL-
positive cells/crypt) in the jejunum (P < 0.001), ileum (P < 0.001), and colon (P = 0.007) 
regardless of time or route of nutrient administration (Figure 4.3B).  
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Mucosal cell differentiation 
Cdx2, a marker of cellular differentiation, was quantified in jejunal, ileal, and colonic 
mucosa to examine changes in mucosal cell maturation. Teduglutide increased (teduglutide = 
0.534 ± 0.026 versus vehicle = 0.473 ± 0.027; P = 0.04) ileal Cdx2 mRNA abundance regardless 
of time and route of nutrient administration, but did not affect Cdx2 mRNA abundance of any 
other segment (data not shown). 
 
Functional adaptations 
Mucosal ion transport 
Basal short circuit current (µA/cm2), transmucosal resistance (Ω*cm2), and potential 
difference (V) were assessed using modified Ussing chambers to evaluate active, passive, and 
total ion transport, respectively. Transmucosal resistance was transiently numerically decreased 
in the duodenum (P = 0.07) of teduglutide- versus vehicle-treated animals, regardless of route of 
nutrient administration. Teduglutide treatment did not affect transmucosal resistance of any other 
intestinal segment, or basal short circuit current or potential difference of any intestinal segment 
(data not shown). 
Mucosal nutrient transport 
Nutrient transport was assessed by measuring deflections in short circuit current induced 
by addition of nutritive substrates to the mucosal chamber medium. Addition of 10 mM D-
glucose was used to assess intestinal monosaccharide transport via the sodium/glucose co-
transporter 1 (SGLT1). Teduglutide treatment resulted in rapid, reversible increases in duodenal 
(P = 0.01), jejunal (P = 0.03) and ileal (P = 0.04) glucose transport (Table 4.1) regardless of 
route of nutrient administration. Glutamine transport, important as a source of fuel for the small 
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intestine, was assessed via addition of 10 mM L-glutamine to the mucosal chamber. Teduglutide 
acutely increased duodenal (P = 0.002) and jejunal (P < 0.001) glutamine transport regardless of 
route of nutrient administration (Figure 4.4). Peptide transport via peptide transporter 1 (PepT1) 
was measured by addition of 10 mM glycyl-sarcosine. Teduglutide increased (teduglutide = 
0.465 ± 0.368 versus vehicle = -3.265 ± 1.18 µA/cm2; P = 0.04) ileal peptide transport at 7 days 
regardless of route of nutrient support, with a trend (P = 0.06) for decreased duodenal peptide 
transport with teduglutide versus vehicle treatment, regardless of time or route of nutrient 
administration. Jejunal peptide transport was not affected by teduglutide. Neural and immune-
based chloride secretion were assessed by sequential addition of 10 mM serotonin (5-HT) and 10 
mM carbmylchloride (CCH), respectively.  Teduglutide did not affect 5-HT- or CCH-mediated 
secretion of any intestinal segment (data not shown).   
 
Question 2: Are the effects of teduglutide in this model complimented or 
synergistically enhanced by the provision of PEN? 
Structural adaptations  
Gross intestinal morphology 
Duodenal and jejunal length were greater in PEN versus TPN animals at day 7 
(duodenum, PEN = 8.91 ± 0.21 versus TPN = 7.11 ± 0.33 cm/kg, P = 0.04; jejunum, PEN = 7.35 
± 0.46 versus TPN = 5.54 ± 0.44 cm/kg, P = 0.04), complementing the action of teduglutide in 
the duodenum. Animals that received both teduglutide and PEN showed trends for greatest 
duodenal (P = 0.051) and colonic (P = 0.13) lengths. Route of nutrient administration did not 
affect wet weight or mucosal mass of any intestinal segment (data not shown).  
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Intestinal tissue composition 
 While teduglutide did not affect DNA concentration of any intestinal segment, colonic 
DNA concentration was greater (PEN = 2.00 ± 0.27 versus TPN = 1.67 ± 0.24 µg DNA/mg; P = 
0.03) in PEN versus TPN animals regardless of drug or time. PEN animals also maintained ileal 
DNA concentration over 48 hours, while that of TPN animals decreased (PEN animals, 4 hours = 
3.05 ± 0.25 and 48 hours = 3.35 ± 0.19 µg DNA/mg; TPN animals, 4 hours = 3.47 ± 0.25 and 48 
hours = 2.67 ± 0.23 µg DNA/mg; P = 0.002) from 4 to 48 hours. PEN did not affect protein or 
protein/DNA concentrations of any intestinal segment (data not shown).  
Crypt-villus architecture 
Jejunal (P = 0.001) and ileal (P = 0.01) villus height were greater in PEN versus TPN 
animals regardless of drug or time, and villus height was numerically greatest in all small 
intestinal segments and at all time points in PEN+ animals (Table 4.2, Figure 4.5). Ileal crypt 
depth was greater (P = 0.002) in PEN versus TPN animals regardless of drug or time, and crypt 
depth was numerically greatest in the 7 day PEN+ group in the jejunum, ileum, and colon (Table 
4.3). 
 Epithelial cell turnover 
While teduglutide increased proliferation in both the small intestine and colon, PEN 
increased proliferation in the small intestine only (duodenum, jejunum, ileum all P < 0.001; 
colon, P = 0.74), regardless of drug or time (Table 4.4). Ileal proliferation was greatest in the 
PEN+ group at all time points (4 hours, P = 0.01; 48 hours, P = 0.09; 7 days, P = 0.09; Figure 
4.6). Similar to teduglutide administration, PEN decreased apoptosis in both the jejunum (PEN = 
1.81 ± 0.04 versus TPN = 2.15 ± 0.05 TUNEL-positive cells/crypt; P < 0.001) and ileum (PEN = 
1.86 ± 0.12 versus TPN = 2.18 ± 0.12 TUNEL-positive cells/crypt; P = 0.009) regardless of drug 
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or time (Figure 4.7). PEN did not affect colonic apoptosis (data not shown). A significant 
route*drug interaction was noted in that PEN decreased (PEN- = 1.93 ± 0.06 versus TPN- = 2.42 
± 0.07 TUNEL-positive cells/villi; P = 0.01) jejunal apoptosis in vehicle control animals, but the 
PEN-induced decrease (PEN+ = 1.70 ± 0.06 versus TPN+ = 1.87 ± 0.06 TUNEL-positive 
cells/villi; P = 0.055) in jejunal apoptosis of teduglutide-treated animals was not significant.   
  Mucosal cell differentiation 
PEN treatment did not affect Cdx2 mRNA abundance in any intestinal segment (data not 
shown). 
 
Functional adaptations 
 Mucosal ion transport 
Ileal transmucosal resistance of PEN animals was transiently increased (P = 0.01) at 48 
hours (Figure 4.8). PEN did not affect jejunal or colonic transmucosal resistance (data not 
shown). While teduglutide did not affect potential difference, duodenal potential difference of 
PEN animals was greater (PEN = 3.40 ± 0.26 versus TPN = 2.38 ± 0.27 mV; P = 0.007) than that 
of TPN animals regardless of time or drug, indicative of increased resistance to charged ions. 
Mucosal nutrient transport 
Converse to the increases in duodenal, jejunal, and ileal glucose transport observed with 
teduglutide treatment, PEN administration decreased (PEN = 22.25 ± 11.3 versus TPN = 41.2 ± 
24.0 µA/cm2; P = 0.049) duodenal glucose transport. PEN acutely increased (PEN = 11.3 ± 4.87 
versus TPN = 4.9 ± 2.40 µA/cm2; P = 0.047) colonic glutamine transport at 4 hours, 
complementing the duodenal and jejunal effects of teduglutide, but PepT1 activity was 
unaffected by route of nutrient administration (data not shown). Finally, while teduglutide did 
not affect CCH-mediated secretory response of any intestinal segment, PEN increased (PEN = 
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39.7 ± 9.5 versus TPN = 15.6 ± 10.4 μA/cm2; P = 0.001) duodenal CCH-mediated secretion 
versus TPN regardless of time or drug. A route*drug interaction was noted in that ileal 5-HT-
mediated secretion was decreased in TPN animals that received teduglutide (TPN+), and in PEN 
animals that received vehicle (PEN-), as compared to animals that received TPN and vehicle 
(TPN-; TPN- = 3.29 ± 1.0, TPN+ = 1.78 ± 1.0, and PEN- = 1.36 ± 1.0 μA/cm2; P = 0.03). 
 
Question 3: Can distinct temporal markers of adaptation stimulated by these two 
therapies be identified?  
PCA 1  
 PCA of data from 4-hour piglets was optimized by removing from the analysis the 
variables that did not load on any factor retained. Redundant variables were also removed as 
described in the methods.  For example, duodenal DNA and protein/DNA concentrations were 
highly correlated (r = 0.84), and duodenal protein/DNA concentration was used for the final 
analysis. The final analysis included 24 pigs and 43 variables. Ten retained factors accounted for 
79.7% of the total variance. The first four factors are shown in Table 4.5, and the remaining 
factors each explained less than 8.0% of the total variance. Crypt depth of all intestinal segments 
accounted for the greatest percent of the total variance at 4 hours. The second and third factors 
were mainly associated with body and individual organ weights. Thus, it appears that teduglutide 
and/or PEN impacted structural indices to a greater extent than functional indices at 4 hours.   
 
PCA 2 
 PCA of data from 48-hour piglets was optimized in the same manner as PCA 1. The final 
analysis included 23 pigs and 52 variables. Ten retained factors accounted for 79.7% of the total 
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variance. The first three factors are shown in Table 4.6. The remaining factors each explained 
less than 8.0% of the total variance. Structural and functional characteristics of the duodenum, as 
well as ileal ion and nutrient transport, accounted for the greatest portion of total variance at 48 
hours. The second and third factors were mainly associated with jejunal structural and functional 
characteristics as well as measures of growth. By 48 hours, functional measures of adaptation 
begin to compliment structural measures. 
 
PCA 3 
 Following optimization, final PCA of data from 7-day piglets included 24 pigs and 48 
variables. Ten retained factors accounted for 80.7% of the total variance. The first four factors 
are shown in Table 4.7. The remaining factors each explained less than 8.0% of the total 
variance. Crypt depth and PCNA of the small intestine and colonic weight and functional 
capacity accounted for the greatest percent of the total variance compared with all other factors 
at 7 days. The second and third factors were mainly associated with small intestinal segment 
length and ion and nutrient transport. Similar to 48 hours, both structural and functional indices 
of adaptation appear to be of importance at this chronic time point. 
 
PCA 4 
 PCA of data from all piglets included 71 pigs and 37 variables after optimization.  
Eighteen retained factors accounted for 82.1% of the total variance. The first four factors are 
shown in Table 4.8, and the remaining factors each explained less than 5.0% of the total 
variance. Crypt depth and PCNA in the small intestine accounted for the greatest percent of the 
total variance in the pooled piglet group. The second, third and fourth factors were mainly 
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associated with small intestinal segment length and nutrient transport within the jejunum and 
ileum. Small intestine structural indices and proximal gut ion and nutrient transport accounted 
for the greatest portion of total variance compared with all other factors in the pooled group of 
piglets. These variables are indicative of differences in intestinal adaptation between groups, and 
support the roles of teduglutide and/or PEN in improving intestinal structural and functional 
indices in this neonatal piglet model of SBS.  
 
DISCUSSION  
 The objectives of this study were three-fold: (1) to investigate the role of teduglutide in 
inducing structural and/or functional measures of adaptation in a neonatal piglet model of SBS; 
(2) to assess complimentary or synergistic effects of combination teduglutide and PEN; and (3) 
to identify distinct temporal markers of adaptation stimulated by these two therapies. This 
neonatal piglet model was chosen due to anatomic and physiologic similarities between neonatal 
piglets and human infants, and because neonatal piglets are a well-characterized model of the 
PN-fed infant19,47 that display full clinical intestinal failure symptoms following massive small 
bowel resection.46 Nutrition support adequacy of this model was  confirmed in that body weight 
did not differ between treatment groups at any time point, and all piglets gained appropriate 
weight over time, regardless of treatment.  
 The interventions utilized in this study were selected due to their efficacy in reducing PN 
dependence in adult patients, as well as their clinical relevancy to the pediatric population. 
Though human pediatric teduglutide trials have yet to be completed, one trial of PN-dependent 
children 1-17 years of age is estimated to be completed in March 2015,52 and another is currently 
enrolling patients with SBS of any age to evaluate the long-term safety profile of teduglutide.53 
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Neonatal piglets with 50% small intestinal resection fed TPN for 7 days43 demonstrated a 
teduglutide-induced dose-dependent increase in weight per length remnant intestine, as well as 
increased intestinal protein fractional synthesis rate with the highest (0.2 mg/kg/d) dose versus 
placebo. However, there were no differences in digestive enzyme activity between groups, 
indicating that while increasing structural adaptation of the remnant intestine, teduglutide had 
limited effects on functional endpoints. Given the limited effects of teduglutide on functional 
indices of adaptation in this model, we investigated complementary and/or synergistic effects 
induced by combination teduglutide and PEN treatment in stimulation of intestinal adaptation. 
 In the current study, beneficial effects of teduglutide and PEN administration were 
similar to those observed in other preclinical trials and adult human studies,25,26,54-59 and 
demonstrate complementary, synergistic roles for teduglutide and PEN in treatment of pediatric 
SBS. Teduglutide and PEN were complementary in anatomical site of action (for example, 
teduglutide treatment resulted in acute increases in duodenal and jejunal glutamine transport, 
while PEN acutely increased glutamine transport within the colon), as well as in both structural 
and functional measures (for example, teduglutide increased colonic wet weight, proliferation, 
and crypt depth as well as decreased colonic apoptosis, while PEN stimulated an increase in 
colonic glutamine transport). Furthermore, the greatest clinical gains were observed in the PEN+ 
group for (1) duodenal and colonic segment length; (2) villus height of all small intestinal 
segments; (3) crypt depth of the jejunum, ileum, and colon; and (4) ileal proliferation. Coupling 
these two therapies represents an opportunity to augment intestinal adaptation beyond that of 
either therapy alone, and potentially accelerate enteral autonomy.      
 An additional important finding from this study was the establishment of crypt depth, 
through PCA, as a strong indicator of neonatal intestinal adaptation following resection 
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regardless of time. As we hypothesized, structural indices preceded functional indices of 
adaptation, and assessment of crypt depth was identified to be a potential reliable, single measure 
to assess overall intestinal adaptation in pediatric SBS. Opportunities to assess crypt depth of 
human patients are limited, but in the event of need for further resection or biopsy, attainment of 
a sample for assessment of crypt depth may be possible.  
 Two piglet studies60,61 have reported a lack of effect of GLP-2 administration on 
prevention of NEC onset. However, these studies were limited in use of GLP-2 rather than 
teduglutide and a subjective clinical scoring system. Thus, despite these two studies, there is 
sufficient preclinical data reported here and elsewhere,43,62 to support establishment of pediatric 
clinical trials of teduglutide for treatment, and potentially prevention, of SBS. In planning trials 
of this vulnerable population, appropriate dosing must be carefully evaluated given that 
teduglutide is eliminated primarily through glomerular filtration,63 which may be at various 
stages of maturation in infants, particularly those born preterm.  Furthermore, changes in 
percentage of total body water may also affect absorption and distribution of teduglutide.62 
Teduglutide did not affect body weight in the current study, but body composition was not 
assessed and the possibility of teduglutide-induced alterations in body composition cannot be 
precluded. However, teduglutide treatment significantly improved body weight of PN-dependent 
adult human subjects versus placebo, and these increases were primarily restricted to changes in 
lean body mass.64,65 Thus, in addition to stimulation of intestinal adaptation, teduglutide may also 
serve to improve protein accretion in the rapidly growing infants. However, due to a paucity of 
data regarding the pharmacokinetics of teduglutide in pediatric patients, care must be utilized to 
ensure the minimum dose capable of stimulating adaptation is used.  
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 The data presented here illustrate an important opportunity to improve the care of infants 
with SBS and increase the efficacy of current treatments to promote enteral autonomy further. 
This work also directly addresses two of the six research areas recently identified by an 
American Society for Nutrition working group “whose advancement will have the greatest 
projected impact on the future health and well-being of global populations.”66 Clearly, 
teduglutide represents an immense opportunity not only for treatment of pediatric SBS, but also 
for potential prophylactic acceleration of gut maturation in preterm infants.   
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FIGURES AND TABLES 
 
 
Figure 4.1. Villus height of small intestinal segments of animals treated with teduglutide or 
vehicle.  
Data are expressed as mean (pooled by drug) ± SEM.  
*P < 0.05 within segment teduglutide versus vehicle.   
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Figure 4.2. Crypt depth of all intestinal segments of animals treated with teduglutide or vehicle. 
Data are expressed as mean (pooled by drug) ± SEM.  
*P < 0.05 within segment teduglutide versus vehicle.  
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Figure 4.3 Epithelial cell (A) proliferation and (B) apoptosis of animals treated with teduglutide 
or vehicle.  
Data are expressed as mean (pooled by drug) ± SEM.  
*P < 0.05 within segment teduglutide versus vehicle.  
Abbreviations: PCNA, proliferating cell nuclear antigen; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling.   
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 Vehicle Teduglutide 
Duodenum (µA/cm2) 
4 hour 22.1 ± 17.0 64.7 ± 31.1* 
48 hour 41.5 ± 28.4 12.5 ± 5.9 
7 day 26.6 ± 10.6 22.6 ± 7.7 
Jejunum (µA/cm2) 
4 hour 29.6 ± 10.7 47.9 ± 13.0* 
48 hour 11.0 ± 15.8 19.2 ± 5.0 
7 day 43.5 ± 10.9 23.0 ± 7.2 
Ileum (µA/cm2) 
4 hour 13.6 ± 4.9 26.5 ± 7.9* 
48 hour 9.7 ± 5.0 5.2 ± 2.2 
7 day 16.2 ± 5.9 14.3 ± 4.5 
 
Table 4.1. Glucose transport within the small intestine of animals treated with teduglutide or 
vehicle.   
Data are expressed as mean (pooled by drug) ± SEM.  
*P < 0.05 within segment and time, teduglutide versus vehicle.  
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Figure 4.4. Glutamine transport within the (A) duodenum and (B) jejunum of animals treated 
with teduglutide or vehicle.  
Data are expressed as mean (pooled by drug) ± SEM.  
Different letters over bars indicate a significant (P < 0.05) within-segment difference.  
 
  
a a 
b b 
b 
b 
0
10
20
30
40
50
4h 48h 7d
G
lu
ta
m
in
e 
tr
a
n
sp
o
rt
 (
µ
A
/c
m
2
)
Time
0
10
20
30
40
50
60
4h 48h 7d
G
lu
ta
m
in
e 
tr
a
n
sp
o
rt
 (
µ
A
/c
m
2
)
Time
a 
b 
b 
b 
b 
b 
A 
Vehicle 
Teduglutide 
B 
b 
a 
 
b 
b 
b 
a 
4 hours 
4 hours 
48 hours 
48 hours 
7 days 
hours 
7 days 
hours 
113 
 
 Vehicle Teduglutide 
 TPN PEN TPN PEN 
Duodenum (µm) 
    4 hours 476 ± 32.5 391 ± 42.1 442 ± 18.4 500 ± 48.7 
    48 hours 409 ± 66.9 447 ± 55.0 487 ± 59.4 515 ± 46.5 
    7 days 313 ± 29.8 405 ± 81.2 487 ± 38.1 507 ± 44.7 
    Mean1 407.1 ± 22.4 489 ± 16.8* 
Jejunum (µm)^ 
    4 hours 593 ± 45.1 605 ± 65.1 644 ± 87.2 670 ± 58.0 
    48 hours 601 ± 38.8 705 ± 42.1 733 ± 42.0 787 ± 70.5 
    7 days 388 ± 42.1 527 ± 50.6 456 ± 65.5 783 ± 51.1 
    Mean1 568 ± 25.2 683 ± 30.6* 
Ileum (µm)^ 
    4 hours 470 ± 41.4 479 ± 30.4 520 ± 53.0 545 ± 46.0 
    48 hours 492 ± 38.4 663 ± 54.9 574 ± 34.4 745 ± 87.5 
    7 days 518 ± 62.9 636 ± 74.8 651 ± 31.6 660 ± 76.1 
    Mean1 544 ± 24.2 612 ± 24.9* 
 
Table 4.2. Villus height within small intestine.  
Data are expressed as mean ± SEM.  
1Pooled by drug.  
*P < 0.05 within-segment, teduglutide versus vehicle.  
^P < 0.05 within segment, pooled by route of nutrient administration; partial enteral nutrition 
(PEN) versus total parenteral nutrition (TPN).  
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Figure 4.5. Mucosal architecture of the (A) duodenum; (B) jejunum; (C) ileum; (D) colon after 7 
days of treatment.  
Representative cross-sectional images of 5µm intestinal tissues with hematoxylin and eosin stain 
at 5× magnification. Scale bars indicate 100 µm.   
Columns: left, tissue from piglets receiving TPN and vehicle control (TPN-); right, tissue from 
piglets receiving PEN and teduglutide (PEN+).  
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 Vehicle Teduglutide 
 TPN PEN TPN PEN 
Duodenum (µm) 
    4 hours 137 ±  9.12 154 ± 6.90 149 ± 11.3 143 ± 9.06 
    48 hours 154 ± 15.5 156 ± 14.0 161 ± 20.7 157 ± 12.9 
    7 days 168 ± 11.1 171 ± 8.64 194 ± 10.2 194 ± 10.1 
    Mean1  157 ± 4.62 167 ± 5.94 
Jejunum (µm) 
    4 hours 131 ± 10.0 129 ± 11.1 130 ± 12.2 134 ± 7.42 
    48 hours 137 ± 10.5 162 ± 16.0 163 ± 17.7 150 ± 10.7 
    7 days 155 ± 9.34 156 ± 7.84 169 ± 8.81 186 ± 4.81 
    Mean1  145.38 ± 4.82 155 ± 5.47 
Ileum (µm)^ 
    4 hours 120 ± 5.57 117 ± 5.62 119 ± 4.64 123 ± 7.91 
    48 hours 113 ± 3.86 131 ± 3.15 132 ± 5.64 140 ± 7.93 
    7 days 123 ± 5.13 140 ± 9.83 138 ± 2.81 169 ± 10.2 
    Mean1  124.26 ± 2.75 137 ± 3.84* 
Colon (µm) 
    4 hours 278 ± 22.2 274 ± 33.7 294 ± 42.3 333 ± 32.7 
    48 hours 287 ± 18.2 301 ± 26.3 328 ± 38.1 321 ± 23.5 
    7 days 264 ± 7.96 299 ± 24.4 339 ± 30.9 347 ± 30.0 
    Mean1  284 ± 8.99 328 ± 12.8* 
 
Table 4.3. Crypt depth of all intestinal segments.  
Data are expressed as means ± SEM.  
1Pooled by drug.  
*P < 0.05 within-segment, teduglutide versus vehicle.  
^P < 0.05 within segment, pooled by route of nutrient administration; partial enteral nutrition 
(PEN) versus total parenteral nutrition (TPN).   
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 TPN PEN P-value 
Duodenum 19.1 ± 0.69 23.1 ± 0.70 < 0.001 
Jejunum 22.5 ± 0.73 26.3 ± 0.72 < 0.001 
Ileum 23.9 ± 0.52 26.5 ± 0.52 < 0.001 
Colon 46.8 ± 2.07 47.5 ± 2.08 0.7369 
 
Table 4.4. Proliferation within all intestinal segments assessed by proliferating cell nuclear 
antigen- (PCNA) positive cells per crypt.  
Data pooled by route of nutrient administration and expressed as mean ± SEM.  
Abbreviations: PEN, partial enteral nutrition; TPN, total parenteral nutrition.  
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Figure 4.6. Ileal proliferation assessed by proliferating cell nuclear antigen- (PCNA) positive 
cells per crypt.  
Data are expressed as means ± SEM.  
Different letters over bars indicate a significant (P < 0.05) within-time difference.  
Abbreviations: PEN-, animals receiving partial enteral nutrition and vehicle control; PEN+, 
animals receiving partial enteral nutrition and teduglutide; TPN-, animals receiving total 
parenteral nutrition and vehicle control TPN+, animals receiving total parenteral nutrition and 
teduglutide.   
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Figure 4.7. Representative slide of ileal epithelial cell apoptosis at 7 days as measured by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining for DNA 
fragmentation.  
Magnification of 20× with DAB stain. Black arrows indicate apoptotic cells.  
Abbreviations: TPN-, total parenteral nutrition vehicle control; PEN+ partial enteral nutrition 
plus teduglutide.   
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Figure 4.8. Ileal transmucosal resistance of total parenteral nutrition- (TPN) and partial enteral 
nutrition- (PEN) fed animals.  
Data are expressed as means ± SEM.  
*P < 0.05 within time, PEN versus TPN.  
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Factor 1 2 3 4 
Variance Explained (%) 11.5 10.5 9.1 8.7 
Cumulative (%) 11.5 22.0 31.1 39.7 
Variable Loading1    
 Duodenum crypt depth 0.76    
 Jejunum crypt depth 0.86    
 Ileum crypt depth 0.77    
 Colon crypt depth 0.70    
 Duodenum PCNA 0.66    
 Duodenum protein/DNA 0.55    
 Colon conductance 0.52    
 Colon CCH 0.57    
 Heart weight  0.72   
 Spleen weight  0.83   
 Pancreas weight  0.62   
 Ileum Cdx2  0.58   
 Duodenum glucose transport  0.81   
 Duodenum short circuit current  0.65   
 Final body weight   -0.71  
 Ileum length   0.66  
 Kidney weight   0.72  
 Jejunum villus height   0.76  
 Jejunum transmucosal resistance   0.70  
 Ileum mucosal mass    0.70 
 Jejunum PCNA    0.54 
 Ileum PCNA    0.74 
 Duodenum CCH    0.60 
 Jejunum glucose transport    0.66 
 Jejunum glutamine transport    0.60 
1Only correlations with |r| ≥ 0.5 are indicated.  
Abbreviations: CCH, carbachol-mediated chloride secretion; PCNA, 
proliferating cell nuclear antigen. 
 
Table 4.5. Major factors obtained by principal component analysis using varimax rotation with 
Kaiser normalization of 43 variables characterizing the gut structure and function of 4 hour pigs.   
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Factor 1 2 3 4 
Variance Explained (%) 16.0 9.8 9.4 7.2 
Cumulative (%) 16.0 25.7 35.1 42.3 
Variable Loading1     
 Duodenum weight 0.74    
 Duodenum length -0.65    
 Ileum DNA -0.77    
 Duodenum mucosal mass -0.58    
 Ileum crypt depth -0.69    
 Duodenum PCNA -0.63    
 Jejunum PCNA -0.83    
 Jejunum TUNEL 0.63    
 Colon Cdx2 0.61    
 Duodenum glutamine transport 0.73    
 Duodenum glycyl-sarcosine transport 0.85    
 Duodenum 5-HT 0.55    
 Jejunum glycyl-sarcosine transport 0.75    
 Ileum glucose transport 0.54    
 Ileum glutamine transport 0.75    
 Ileum 5-HT 0.69    
 Colon short circuit current -0.50    
 Duodenum glucose transport 0.60 0.57   
 Jejunum weight  -0.58   
 Jejunum length  0.68   
 Duodenum conductance  0.80   
 Jejunum conductance  0.88   
 Jejunum CCH  0.71   
 Daily weight gain   0.85  
 Final body weight   0.81  
 Colon length   -0.81  
 Heart weight   -0.79  
 Spleen weight   -0.55  
 Jejunum Cdx2   0.68  
 Duodenum DNA    -0.54 
 Duodenum crypt depth    0.62 
 Colon PCNA    0.75 
 Colon 5HT    0.82 
 Jejunum crypt depth    0.58 
1Only correlations with |r| ≥ 0.5 are indicated. 
Abbreviations: 5-HT, serotonin-mediated chloride secretion; CCH, carbachol-
mediated chloride secretion; PCNA, proliferating cell nuclear antigen; TUNEL, 
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling. 
  
Table 4.6. Major factors obtained by principal component analysis using varimax rotation with 
Kaiser normalization of 52 variables characterizing the gut structure and function of 48 hour pigs.  
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Table 4.7. Major factors obtained by principal component analysis using varimax rotation with 
Kaiser normalization of 48 variables characterizing the gut structure and function of 7 day pigs.  
 
  
Factor 1 2 3 4 
Variance Explained (%) 11.6 10.6 9.4 8.4 
Cumulative (%) 11.6 22.2 31.7 40.0 
Variable Loading1    
 Daily weight gain 0.53    
 Colon weight 0.56    
 Duodenum villus height 0.76    
 Duodenum crypt depth 0.78    
 Jejunum crypt depth 0.86    
 Colon crypt depth 0.71    
 Duodenum PCNA 0.72    
 Ileum PCNA 0.76    
 Colon conductance 0.62    
 Colon CCH 0.54    
 Ileum TUNEL -0.59    
 Duodenum length  0.73   
 Jejunum length  0.72   
 Ileum length  0.85   
 Colon length  0.78   
 Liver weight  -0.82   
 Jejunum mucosal mass  0.56   
 Ileum villus height  0.62   
 Duodenum glucose transport   0.74  
 Jejunum conductance   0.62  
 Jejunum glutamine transport   0.72  
 Jejunum glycyl-sarcosine transport   0.87  
 Ileum glutamine transport   0.62  
 Ileum glycyl-sarcosine transport   0.83  
 Ileum 5-HT    0.86 
 Ileum CCH    0.89 
 Colon glucose transport    0.92 
 Colon glutamine transport    0.62 
 Jejunum DNA    -0.53 
 Colon 5-HT    0.64 
1Only correlations with |r| ≥ 0.5 are indicated. 
Abbreviations: 5-HT, serotonin-mediated chloride secretion; CCH, 
carbachol-mediated chloride secretion; PCNA, proliferating cell nuclear 
antigen; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP 
nick end-labeling. 
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Factor 1 2 3 4 
Variance Explained (%) 8.7 7.6 5.5 5.0 
Cumulative (%) 8.7 16.3 21.8 26.8 
Variable Loading1     
 Duodenum crypt depth 0.53    
 Ileum crypt depth 0.71    
 Duodenum PCNA 0.74    
 Jejunum PCNA 0.81    
 Ileum PCNA 0.75    
 Ileum TUNEL -0.74    
 Final weight  -0.67   
 Duodenum length  0.76   
 Jejunum length  0.74   
 Ileum length  0.79   
 Duodenum mucosal mass  0.55   
 Jejunum conductance   0.85  
 Jejunum glutamine transport   0.81  
 Ileum 5-HT    0.88 
 Ileum CCH    0.91 
1Only correlations with |r| ≥ 0.5 are indicated. 
Abbreviations: 5-HT, serotonin-mediated chloride secretion; CCH, 
carbachol-mediated chloride secretion; PCNA, proliferating cell 
nuclear antigen; TUNEL, terminal deoxynucleotidyl transferase-
mediated dUTP nick end-labeling. 
 
Table 4.8. Major factors obtained by principal component analysis using varimax rotation with 
Kaiser normalization of 37 variables characterizing the gut structure and function of all pooled 
piglets.  
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CHAPTER 5 
A NOVEL NEONATAL FEEDING INTOLERANCE AND NECROTIZING 
ENTEROCOLITIS RISK SCORING TOOL IS EASY TO USE AND VALUED BY 
NURSING STAFF 
 
 
ABSTRACT  
Background: Preterm infants are at increased risk of developing feeding intolerance and 
necrotizing enterocolitis (NEC). Comprehensive, targeted nursing assessments can evaluate the 
risk for and identify early signs of these conditions in an effort to prevent their destructive 
sequela. Purpose: Develop an easy to use scoring tool valued by nurses to predict infant feeding 
intolerance and necrotizing enterocolitis risk. Methods: A novel risk scoring nursing tool was 
implemented in the University of Illinois-affiliated Carle Foundation Hospital (CFH) 48-bed 
level III neonatal intensive care unit (NICU). Data was collected from all preterm infants with 
parental consent during the initial 6 month study period. Scoring accuracy, ease of use, and 
nurses’ attitudes toward the tool were assessed at the study site and by evaluators at a national 
neonatal nursing conference. Results: Fourteen nurses scored 166 tools on 62 infants. Sixteen 
tools (9.6%) contained errors. Mean study site tool ease of use was 8.1 (SD 2.2) on a 10-point 
scale. Ninety percent of conference evaluators agreed/strongly agreed that the tool addressed 
important knowledge gaps. Implications for Practice: The tool is easy to use and valued by 
nurses. Widespread implementation is expected to be a clinically feasible means to improve 
infant clinical outcomes for minimal time and financial cost. Implications for Research: Tool 
validation and refinement based on nursing feedback will improve its broad applicability and 
predictive utility. 
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WHAT THIS STUDY ADDS 
- Identifies clinical factors nursing staff can evaluate relevant to feeding intolerance and NEC. 
- Establishes the acceptability and feasibility of implementation of a novel nursing tool to assess 
neonatal feeding intolerance and NEC risk. 
- Provides clear next steps for tool improvement and validation.    
 
INTRODUCTION 
 In 2013, 11.4% of births in the United States occurred preterm.1 Due to the immaturity of 
the gastrointestinal tract, these infants are at increased risk of developing feeding intolerance and 
necrotizing enterocolitis (NEC). NEC is the most common surgical emergency among infants 
and proves fatal for 25-33% of infants diagnosed with the disease.2,3 NEC is also the second 
leading cause of morbidity in preterm infants, including both short- and long-term 
gastrointestinal complications as well as impaired neurodevelopment.4 Total annual cost of care 
for infants with NEC in the United States is between $500 million and $1 billion.5 The multi-
factorial, fulminant nature of NEC makes medical and/or surgical management difficult, so 
efforts aimed at prevention and early detection, rather than development and application of new 
treatments following full disease onset, will be most effective in reducing infant morbidity and 
mortality.5 Furthermore, because NEC is difficult to diagnose, nursing assessments provide 
assistance in identifying early signs of feeding intolerance and NEC.6 Consistency in nursing 
assessments and early interventions could lead to better clinical outcomes for these vulnerable 
patients.  
Although the substantial potential for sensitive and specific NEC risk assessment and 
early detection to improve patient outcomes has been broadly recognized,5,7,8 no approach to date 
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has effectively addressed this issue. Numerous previous investigations have attempted to develop 
prediction models based on individual clinical findings such as gestational age at birth,9 birth 
weight,10 feeding practices,11,12 or antibiotic administration,13 and a comprehensive NEC risk 
score was developed in 1985,14 but later demonstrated to lack validity.7 A new integrated risk 
tool built through expert consensus and statistical modeling is currently undergoing direct 
clinical testing,15-17 but this recent effort has not assessed the crucial aspect of feasibility of 
nursing implementation. Furthermore, as retrospective data may be miscoded, of low quality, or 
altogether missing,16 the predictive ability of risk scoring tools should be prospectively 
validated.18 Given the limitations of previous work in this area, the overall goal of this work is to 
develop a prospectively validated, evidence-based, simple to use bedside tool valued by nurses to 
predict infant feeding intolerance and NEC risk. The objective of the pilot phase presented here 
is to assess tool ease of use and nurses’ attitudes toward the tool since a tool that is difficult to 
use or interpret will be of little value in a busy neonatal intensive care unit (NICU). Based on 
extensive literature review of factors pertinent to NEC development,19,20 as well as the success of 
similarly designed nursing tools,21,22 we hypothesized that nurses will value and find the tool 
easy to use. 
 
METHODS 
 
 Construction of the feeding intolerance and necrotizing enterocolitis risk scoring 
tool 
 Multiple databases, including Medline and Embase, were searched using predefined 
search criteria to identify factors relevant to development of feeding intolerance and NEC in 
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preterm infants. Five categories of germane variables were identified, including gestational age 
at birth, birth weight, infant feeding substance, postnatal infant factors, and perinatal maternal 
factors. These five categories of variables were populated with multiple risk factors, each 
assigned a numeric point value ranging from 1-3. Point values were assigned based on the level 
of evidence available to support inclusion in the tool. The numeric score generated upon tool 
completion, ranging from 1-44, reflects the sum of points from each risk factor. A score of 1-5 
places infants in the low risk category, 6-8 in the moderate risk category, and 9 or more in the 
high risk category. The tool (Table 5.1) was modeled after existing nursing tools21,22 in an effort 
to enhance familiarity and ensure its wide acceptance. It was designed to be utilized at admission 
and weekly until discharge. 
  
Tool pilot and formal testing 
 A paper-based version of the tool was pilot tested as part of a nursing protocol 
improvement project in the University of Illinois-affiliated Carle Foundation Hospital (CFH) 48-
bed level III NICU, which provides complete care for infants born ≥ 22 weeks gestation. The 
tool was utilized by both day and night shift bedside nurses with 2-20 years of nursing 
experience. Following pilot testing, an electronic version of the tool was integrated into the 
electronic medical records (EMR) system. Preterm infants (gestational age at birth < 37 weeks) 
admitted during the initial 6 month study period with parental consent were followed throughout 
their NICU hospitalization. Data was collected from the EMR by nursing and protocol staff.  
Feasibility of tool use was evaluated by scoring accuracy of all tools completed during the initial 
study period. Anonymous, electronically-administered surveys were conducted at CFH and 
following tool presentation at the 2013 National Association of Neonatal Nurses (NANN) 
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conference to assess tool ease of use and nurses’ attitudes toward the tool. The study was 
approved by the CFH and University of Illinois Institutional Review Boards (IRB).  
 
RESULTS 
 
 Pilot testing  
A total of 188 paper-based tools, scoring 72 infants, were completed during the pilot 
study. Infant risk category (low, moderate, or high) was accurately determined in 94.7% of the 
completed tools, but errors in total point value determinations were frequent. Thus, the 
electronic, EMR-integrated version of the tool was created which includes drop-down menus, 
check boxes, and automatic score totaling.    
  
Formal Testing 
 Study subjects  
 Sixty-three infants were enrolled in the initial 6 month study period, including 9 pairs of 
twins and 2 sets of triplets. Gestational age at birth ranged from 22 weeks and 6 days to 36 weeks 
and 5 days. Twelve (19.0%) infants were normal birth weight, 25 (39.7%) low birth weight, 19 
(30.2%) very low birth weight, and 7 (11.1%) extremely low birth weight. Thirty-nine (61.9%) 
were male. Fourteen nurses scored a total of 166 tools in the initial 6 month study period. 
Excluding tools scored by the protocol nurse (124 tools on 57 infants), nurses completed an 
average of 3.32 tools on 2.77 infants. Thirteen (7.8%) tools classified the infant as low risk, 25 
(15.1%) as moderate risk, and 128 (77.1%) as high risk. 
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Tool implementation at Carle Foundation Hospital    
 Sixteen errors were made in the 166 scored tools, but as the number of tools scored by a 
particular nurse increased, the proportion of tools containing an error decreased. CHF survey 
respondents (n = 28) had < 1 to > 15 years of nursing experience, and the highest degree of 
education attained ranged from an associate degree to a master of science or master of science in 
nursing (Table 5.2). The mean ease of use ranking on a scale from 1 (very hard) to 10 (very 
easy), was 8.1 (SD 2.2). Twenty-one (75.0%) nurses ranked the ease of use as 8 or higher (Table 
5.2). All 28 (100%) respondents replied “yes” when asked if the tool raised their awareness of 
factors contributing to feeding intolerance and NEC development. All 28 (100%) also responded 
“yes” when asked if they believe the tool accurately identifies babies at risk of developing 
feeding intolerance or NEC. When asked whether knowing a baby's risk (low, moderate, or high) 
provides better information to care for the baby, 20 (71.4%) nurses stated that it does. One 
(3.6%) said that it sometimes does, and commented that the care an infant receives is determined 
primarily by the provider on duty. Seven (25.0%) nurses responded negatively, of which 3 noted 
that that NICU nurses are highly vigilant and monitor babies closely regardless of the tool’s risk 
determination.   
NANN evaluator assessment of tool 
 More than 80% of surveyed NANN evaluators (Table 5.3) work in neonatal care full-
time, and 71% have been in neonatal care ≥ 11 years and are certified in a specialty. Seventy-
nine percent practice in a level III NICU, and 31% are advanced practice nurses, having post-
graduate nursing education. Mean response when asked, on a scale of 1 (strongly disagree) to 5 
(strongly agree), whether the tool addresses important gaps in knowledge in the field (n = 109) 
was 4.45 (SD 0.75; Table 5.3). Ninety-eight (89.9%) evaluators agreed or strongly agreed. 
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Eighty-eight (53.0%) of 166 evaluators thought the session provided information that would 
change the clinical care they provide, and 15 respondents commented that they would like to 
implement the tool at their institution. When asked if they would attempt to utilize session 
information to implement changes in their competence, performance, and/or patients' outcomes 
(n = 146), 88 (60.3%) evaluators indicated that they would, with 27 commenting the information 
would be used for staff education at their institution. Twelve evaluators commented that the tool 
did not include any new information or practices. Two evaluators stated that the tool may be 
useful for new nurses, but not advanced practice nurses or those with many years of experience, 
and 3 noted that the tool requires validation.   
 
DISCUSSION 
Accurately representing the factors that contribute to feeding intolerance and NEC on a 
comprehensive, practical nursing tool has the potential to dramatically improve infant outcomes 
through earlier, individually-tailored treatment. However in order to be effective, the tool must 
be perceived as valuable by nurses, and be as simple, consistent, and objective as possible since a 
tool that is difficult to use or interpret will be of little value in a busy NICU. Previous and other 
ongoing studies have not addressed this facet of tool development, and this is a strength of the 
novel tool presented here. 
Both the CFH and NANN nursing surveys demonstrate the tool’s importance to the field 
of neonatal nursing, nurses’ positive attitudes toward, and willingness to utilize, the scoring tool.  
These results are tremendously encouraging in that nurses are well-versed in the use of the EMR 
system, and the potential to positively impact infant clinical outcomes through tool use is 
substantial compared to the minimal nursing effort required to complete the tool. However, the 
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results presented here also highlight the opportunity for further research regarding tool 
improvement. Three of 5 CFH nurses who ranked the tool’s ease of use as ≤ 5 had an associate’s 
degree as their highest level of education.  While this low ease of use ranking may simply be due 
to a lesser degree of familiarity with the tool, it also suggests the possibility that tool training 
should be tailored to education level. This possibility is reinforced by the comment regarding 
insufficient training noted by the nurse who ranked the tool’s ease of use as a 2. Additionally, 5 
nurses commented that finding perinatal maternal factors can be difficult, so further training on 
this issue is currently being implemented.   
In addition to tailored/further training, the tool is currently undergoing validation of 
included risk factors, and point values assigned to those factors. Assessment of multiple 
measures of consistency and reliability, as well as construct validity, sensitivity, specificity, and 
positive and negative predictive values is ongoing. Optimal risk category cut off ranges, which 
were initially assigned arbitrarily, are also being optimized to better correlate with infant 
outcomes. Tool implementation is demonstrated here to be feasible at a single institution, but 
future work following validation may involve implementation at additional institutions, and 
potential inclusion of an institutional NEC risk factor.15  
These ongoing and future steps will be crucial in ensuring a broadly applicable risk 
scoring tool that can maximally improve infant outcomes for minimal time and financial cost. 
Validation and further development of this tool has potentially wide-reaching implications for 
practice including the ability to (1) provide NICU doctors and nurses with a practical, objective 
means by which to assess infant risk of feeding intolerance and NEC, (2) better know when, and 
for which infants, to institute preventative measures at the earliest possible time so that the 
destructive sequela of NEC can be avoided, (3) save resources through targeted personalized 
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medicine, and (4) ultimately utilize this tool as a validated screening device for future research 
focused on development and implementation of new feeding intolerance and NEC interventions 
or to validate potential biomarkers of NEC.   
 
SUMMARY OF RECOMMENDATIONS FOR PRACTICE AND RESEARCH 
  
What we know 
- Comprehensive nursing assessments have the potential to dramatically improve infant 
outcomes through early identification of signs of feeding intolerance and NEC.   
- Previous and other ongoing efforts to develop NEC risk scoring tools have not assessed the 
crucial aspect of feasibility of nursing implementation.  
- Nurses are willing to use and have positive attitudes toward the tool presented here.  
 
 What needs to be studied 
- Optimization of training regarding tool use. 
- Validation of factors included in the tool and point values assigned to those factors in order to 
maximize tool sensitivity and specificity.  
 
 What we can do today  
- Become familiar with the clinical characteristics of feeding intolerance and NEC, and 
encourage vigilance of its signs among all neonatal nurses. 
- Improve tool ease of use based on the nursing feedback presented here. 
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FIGURES AND TABLES 
 
Points Variable Category and Risk Factors 
Gestational Age at Birth (select one) 
1 32 - 36 6/7 weeks (preterm) 
2 28 - 31 6/7 weeks (very preterm)            
3 < 28 weeks (extremely preterm)            
Birth Weight (select one) 
0 ≥ 2500 g 
1 1500 - 2499 g (low birth weight) 
2 1000 - 1499 g (very low birth weight)                
3 < 1000 g (extremely low birth weight)       
Feeding Substance (select all that apply) 
0 Mother’s own milk  
1 Donor breast milk 
1 Bovine human milk fortifier                              
3 Bovine-based formula           
Postnatal Infant Factors (select all that apply) 
1 Red blood cell transfusion  
1 Congenital heart disease or patent ductus arteriosis 
2 Polycythemia (hematocrit > 60) 
2 Respiratory distress (> 24 hours assisted ventilation)  
3 Hypoxia/asphyxia at birth 
3 Sepsis 
3 Antibiotics for ≥ 5 days 
3 Intrauterine growth restriction or small for gestational age 
Perinatal Maternal Factors (select all that apply) 
1 Cigarette use during pregnancy                                                                   
2 Placenta abruption                                                                                           
2 Clinical chorioamnionitis  
2 Illicit drug use during pregnancy                                                                                            
2 Preterm premature rupture of membranes  
2 Prolonged rupture of membranes  (≥ 18 hours)    
3 Incomplete or no antenatal glucocorticoid therapy  
3 Absent or reversed end diastolic flow to infant  
 
Table 5.1. Feeding intolerance and necrotizing enterocolitis risk scoring tool.10,23-26 Scoring risk 
ranges: 1-5, low; 6-8, moderate; ≥ 9, high.   
141 
 
CFH respondent demographics (n = 28) 
Response  
n %   
Years of nursing experience 
  0-5 5 17.9   
  6-10 11 39.3   
  11-15 4 14.3   
  > 15 8 28.6   
Highest degree of education completed 
  Associate 7 25.0   
  BS or BSN 16 57.1   
  MS or MSN 2 7.1   
  Nursing school diploma 3 10.7   
 CFH survey question 
Response   
n % Comments (n) 
Rank the ease of use of the tool.  
  1 (very difficult) 0 0    
  2 1 3.6 Received insufficient training on tool use (1)  
  3 1 3.6  
  4 0 0  
  5 3 10.7 Can be difficult to find maternal factors (2) 
  6 0 0  
  7 2 7.1  
  8 6 21.4 Can be difficult to find maternal factors (2)  
  9 6 21.4 Can be difficult to find maternal factors (1)  
  10 (very easy) 9 32.1    
  Mean (SD) 8.1 (2.2)  
Has the tool raised your awareness of risk factors that contribute to feeding intolerance and NEC? 
  Yes 28 100   
  No 0 0   
Do you believe the tool accurately identifies babies at risk of developing feeding intolerance or NEC? 
  Yes 28 100   
  No 0 0   
Does knowing a baby's risk provide you with better information to care for the baby? 
  Yes 20 71.4   
  No 7 25.0 Monitor infants closely regardless of score (3) 
  Sometimes 1 3.6 Infant care dependent on provider (1)  
  
Table 5.2. Carle Foundation Hospital (CFH) survey respondent demographics and results. 
Abbreviations: BS, bachelor of science; BSN, bachelor of science in nursing; MS, master of 
science; MSN, master of science in nursing; SD, standard deviation.   
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NANN Evaluator Demographics %   
Work full time in neonatal care 80   
Work in level III NICU 79   
In neonatal care ≥ 11 years and certified in a specialty 71   
Advanced practice (post-graduate education) 31   
  Response   
NANN Survey Question  n % Comments (n) 
The session addressed important gaps in knowledge in the field. (n = 109) 
  1 (strongly disagree) 0 0 
 
  2 3 2.6 
  3 8 7.3 
  4 35 32.1 
  5 (strongly agree) 63 57.8 
  Mean (SD) 4.45 (0.75) 
Did the session provide information that will change the clinical care you provide? (n = 166)  
  Yes 88 53.0 
Like to implement tool at home institution (15)  
Think tool is helpful (14) 
     
  No 78 47.0  
Will you attempt to address these changes in order to implement changes in your 
competence, performance, and/or patients’ outcomes? (n = 146)  
 Yes 88 60.3 
Use tool for staff education (27)  
Aid critical thinking (1) 
Guide own further research (1)  
     
 No 58 39.7 
No new information/practices (12) 
Useful for novice, but not experienced or advanced 
practice nurse (2)  
Tool requires validation (3) 
 
Table 5.3. National Association of Neonatal Nurses (NANN) evaluator demographics and survey 
results. Abbreviations: NICU, neonatal intensive care unit; SD, standard deviation.   
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CHAPTER 6 
 
DISCRIMINATION OF FEEDING INTOLERANCE AND NECROTIZING 
ENTEROCOLITIS RISK IN THE PRETERM INFANT IS POSSIBLE USING A NOVEL 
RISK SCORING TOOL 
 
 
ABSTRACT 
 The etiologies of feeding intolerance and necrotizing enterocolitis (NEC) are complex, 
and accurately representing the variables that contribute to these conditions on a single, practical 
risk scoring tool has the potential to dramatically improve infant outcomes through earlier, 
individually-tailored treatment. Preliminary results (Chapter 5) demonstrate nurses’ positive 
attitudes toward a novel neonatal feeding intolerance and risk scoring tool as well as general ease 
of use. The objective of this work was to simplify the tool, reevaluate its clinical utility, and 
assess its accuracy, consistency, inter-rater reliability, and validity. Methods: Anonymous, 
electronically-administered surveys were used to assess study site nurses’ attitudes toward the 
tool, as well as its estimated completion time. Tool error rate and consistency (Cronbach’s alpha) 
were calculated, and inter-rater reliability was assessed by the intraclass correlation coefficient 
(ICC) and Fleiss’ kappa. Risk factors significant to the development of feeding intolerance (days 
with emesis, abdominal distention, or gastric residuals > 50% of previous feeding volume) and 
NEC were identified through chi-square testing. Tool discrimination for each of the four 
outcomes was evaluated using a receiver operating characteristic (ROC) curve. Construct 
validity of each variable category included on the tool was assessed using Pearson’s correlation 
coefficient and independent t-test. The tool was also compared to another published NEC risk 
scoring tool,1 GutCheckNEC, using Pearson correlation coefficients and independent t-test. 
Following these assessments, the tool was optimized and its predictive and construct validity 
reassessed. Results: Mean ease of use on a scale from 1 (very difficult) to 10 (very easy) was 6.9 
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(SD 1.9). Mean time to complete the tool was 4.2 minutes (range: 1-10 minutes). Error rate 
(9.2%), Cronbach’s alpha (0.71), ICC (0.99), and Fleiss’ kappa (1.00) were in acceptable ranges. 
Gestational age at birth, hypoxia/asphyxia at birth, red blood cell (RBC) transfusion, and 
congenital heart disease/patent ductus arteriosis (PDA) were significantly associated with all four 
outcome measures. Total optimized tool score was also associated with all 4 outcome measures 
(area under the ROC curve (AUC) and diagnostic odds ratio (OR) estimates [95% CI]: emesis, 
AUC = 0.69 and OR = 1.14 [1.06, 1.23]; abdominal distention, AUC = 0.82 and OR = 1.28 
[1.18, 1.41]; gastric residuals > 50% previous feeding volume, AUC = 0.64 and OR = 1.11 [1.04, 
1.20]; NEC, AUC = 0.90 and OR = 1.29 [1.12, 1.56]).  Pearson correlation coefficient for the 
optimized tool and GutCheckNEC was 0.82 (P < 0.001), and similar correlation coefficients were 
demonstrated for the two tools for each of the four outcome measures. Scores of infants who did 
and did not develop each of the outcome measures were significantly different using both the 
optimized tool and GutCheckNEC. Conclusions: The tool represents a clinically feasible means to 
discriminate infants at risk of feeding intolerance and NEC. Further refinement will improve its 
clinical utility and allow for implementation at additional institutions.  
 
INTRODUCTION 
Necrotizing enterocolitis (NEC) is a progressive disease in which general feeding 
intolerance and other nonspecific signs may present in advance of gastrointestinal signs.2,3 These 
signs are not limited to, but commonly include, intrauterine growth restriction (IUGR) or low 
birth weight,4-6 prolonged empiric antibiotic administration,7,8 maternal cocaine use,9,10 
chorioamnionitis,11,12 formula feeding,13,14 red blood cell (RBC) transfusion,15,16 and 
prematurity.17 Strong nursing assessment skills and an integrated understanding of how 
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combination of these individual risk factors contribute to NEC may allow for heightened 
vigilance and early NEC detection. Early detection may in turn prevent infant mortality as 
evidenced by a cohort study in which infants who died of NEC were diagnosed an average of 3 
day-of-life days later than those who survived.3 Nurses are instrumental in detecting and 
communicating early signs of NEC,18 and a standardized means by which to assess and 
communicate this risk may ensure application of timely, targeted interventions.  
Early detection of NEC is complicated not only by its multifactorial nature, but also 
because information germane to its development is often found in multiple, disparate places 
within the electronic medical record (EMR), making integration of this information difficult. Use 
of a composite risk score may facilitate meaningful assimilation of this information by the 
clinician19 in much the same was as an Apgar score has been used for decades as a concise index 
of early neonatal clinical condition.  
The first NEC risk prediction score was developed 20 years ago based on a retrospective 
cohort of 29 infants in a single center.20 However, using a single center case-control design, this 
method later resulted in scores of NEC-free infants that were higher (indicative of increased risk) 
than those of infants that ultimately developed NEC.20,21 More recently, a new risk index 
(GutCheckNEC) was developed based on evidence synthesis, expert consensus, and statistical 
modeling.1 Though prospective clinical testing of GutCheckNEC is underway, it is limited in that 
its validation was completed via retrospective database analysis, and because it has not yet 
addressed the crucial factor of nursing acceptance and feasibility of use.  
The overall goal of this work is to develop a prospectively validated, evidence-based, 
simple to use bedside nursing tool to predict preterm infant feeding intolerance and NEC risk. 
Pilot results (Chapter 5) identified clinical factors nursing staff could evaluate relevant to feeding 
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intolerance and NEC development, and established the feasibility of implementation of this 
novel nursing tool. The pilot study also provided clear next steps for tool improvement and 
validation, which are addressed here.  
 
METHODS  
 
 Tool development, subjects, and study site 
 A novel neonatal feeding intolerance and NEC risk scoring tool was developed and 
implemented in the University of Illinois-affiliated Carle Foundation Hospital (CFH) 48-bed 
level III neonatal intensive care unit (NICU) as previously described (Chapter 5). The study was 
approved by the CFH and University of Illinois Institutional Review Boards. Following this pilot 
study, infant enrollment and nursing tool use continued as previously described, and the 
following changes were made to the tool. 
Nil per os (NPO) and total parenteral nutrition (TPN) were added to the feeding category 
for 1 point each. These options previously did not appear within the tool, leading to confusion of 
how to categorize feeding of infants that were receiving TPN or were NPO. Additionally, the 
RBC transfusion risk factor was assigned 2 points rather than 1, as recommended by the study 
site neonatologists and as evidenced in the recent literature.15 The tool was also relocated from 
its own flow sheet within the EMR to the Vitals flow sheet. This sheet is frequently used, 
reducing the need to toggle back and forth to additional flow sheets or areas within the chart. An 
attempt was also made to split the tool into “static” and “dynamic” factors so that static factors 
which remain constant over time (for example, birth weight and gestational age at birth) could be 
carried forward and automatically populated each time the tool was completed for a given infant. 
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However, this was impossible due to limitations in EMR coding and organization. Additional 
training on tool use was also provided to nurses as part of a mandatory EMR upgrade 
information session. 
 
 Outcome measures 
 Feeding intolerance was defined as an inability to digest enteral feedings due to 
ineffective or uncoordinated bowel activity22 as evidenced by (1) abdominal distension and/or 
emesis, (2) gastric residual volumes greater than 50% of previous feeding volume, or (3) a 
disruption in the feeding plan.23 Using this definition, outcome measures included the number of 
days with emesis, abdominal distention, and gastric residuals > 50% of previous feeding volume. 
Number of days, rather than volume of emesis or degree of abdominal distention was used since 
individual nursing assessments of staged photos of an infant’s abdomen and emesis amounts 
vary widely.24 All enrolled infants experienced at least one disruption in feeding plan (ICD-9 
779.31 and 787.3).25 Thus, this was not utilized as an outcome measure. Diagnosis of NEC (ICD-
9 557.0, 777.50, 777.51, 777.52, or 777.53)25 was also used as an outcome measure. 
 
 Feasibility of nursing use 
 As follow-up to the initial nursing survey conducted during the pilot study (Chapter 5), a 
second electronically-administered anonymous survey of study site nurses to re-assess tool 
feasibility of use was conducted. The survey was approved by both the CFH and University of 
Illinois Institutional Review Boards, and responses were voluntary. 
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Tool error rate and scoring consistency 
 Tool error rate was calculated, and scoring consistency of variable categories (gestational 
age at birth, birth weight, feeding, maternal factors, and infant factors) included on the tool were 
assessed using Cronbach’s alpha.26 
 
 Inter-rater reliability 
Inter-rater reliability of both total tool score and risk category determination (high, 
moderate, or low) was evaluated with the intraclass correlation coefficient (ICC) and Fleiss’ 
kappa, respectively.27 A subset of 147 tools completed by 38 nurses was used to calculate the 
ICC and Fleiss’ kappa to allow for examination of equivalence of ratings obtained by distinct 
raters of given infant on a given day, since infant scores may change over time.    
 
 Identification of risk factors significant to feeding intolerance and NEC 
Individual risk factors included in the tool significant to the development of each of the 
four outcomes measures were identified by chi-square testing. Factors common to the 
development of all four outcome measures were identified as underlying common factors 
relevant to the development of feeding intolerance and NEC.  
 
 Predictive validity 
 Logistic regression was conducted for each of the four outcome measures against total 
tool score. Tool discrimination was tested using receiver operating characteristic (ROC) curves 
for each of the four outcome measures using the median value of each outcome as respective cut-
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points. The diagnostic odds ratio (OR) for each of the four outcome measures was also 
determined. 
 
 Construct validity and comparison with GutCheckNEC  
 Construct validity was evaluated by independent t-test to determine whether a difference 
existed between mean scores of infants who did and did not ultimately develop each of the four 
outcome measures. As GutCheckNEC contains overlapping, but also unique risk factors, 
GutCheckNEC scores were calculated for all infants enrolled in this study. Independent t-test was 
similarly used to determine whether a difference existed between mean GutCheckNEC scores of 
enrolled infants who did and did not ultimately develop each of the four outcome measures. 
Median values of each outcome were used as respective cut-points. Overall correlation between 
the two tools, as well as the correlation of the total score generated with each tool to each of the 
four outcome measures, was assessed with the Pearson correlation coefficient.  
 
 Tool optimization 
 The tool was optimized by removing factors which were not significant to the 
development of at least two of the three feeding intolerance outcomes, or to the development of 
NEC. Additional factors suggested in the literature to be significant to feeding intolerance and/or 
NEC development were also evaluated. This included gender, race, cesarean section versus 
vaginal delivery, singleton versus multiple gestation, outborn versus inborn, Apgar scores at one 
and five minutes, metabolic acidosis, hypotension treated with inotropic medication, placental 
abnormality, and maternal hypertension. If a significant correlation (P < 0.05) existed between 
pairs of factors assessing similar constructs, only the factor significant to the development of a 
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greater number of the four outcomes was retained. Factors were assigned 1 point for each of the 
four outcome measures they were significant to the development of.  The tool was reassessed for 
predictive and construct validity as described above. Validation was also utilized to determine a 
single “at risk” threshold, simplifying the risk category determination to either “at risk” or “not at 
risk.” All statistical procedures were completed using SAS (Version 9.4; SAS Institute, Cary, 
NC).  
 
RESULTS 
 
 Tool development and study subjects  
 The modified tool is shown in Table 6.1. From August 2013 to December 2014, 49 
nurses scored 499 tools on the 133 enrolled infants. Gestational age at birth of enrolled infants 
ranged from 22 weeks and 6 days to 36 weeks and 6 days, and included extremely low, very low, 
low, and normal birth weight infants (Figure 6.1). Eighteen 18 pairs of twins, 2 sets of triplets, 
and 89 singleton infants were enrolled. Seventy-six (57.1%) were male.  
 
 Feasibility of nursing use 
Of 42 nurses who responded to the survey, 60.5% had ≥ 6 years of nursing experience. 
73.8% held a Bachelor of Science or Bachelor of Science in Nursing, 23.8% an Associate 
degree, and 2.4% a nursing school diploma. Survey results are shown in Table 6.2. Briefly, 
83.3% of nurses surveyed had used the tool at least six times. Ease of use ranking on a scale of 1 
(very difficult) to 10 (very easy) was 6.9 (SD 1.9), and mean time to complete the tool was 
estimated to be 4.2 minutes (range: 1-10 minutes).  When asked if the tool raised had raised his 
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or her awareness of risk factors that contribute to feeding intolerance and NEC, 97.6% of nurses 
responded that it had. Similarly, 81.0% of nurses said the tool provides them with better 
information to care for an infant, and 85.7% stated they would be willing to use it at least daily 
for an infant under their care. However, 76.2% said the tool could be improved to make it easier 
to use, with comments most frequently related to the difficulty in finding maternal information 
within the EMR.  
 
 Tool error rate and scoring consistency 
 Forty-six tools (9.2%) contained errors, with 50 total errors yielding an item selection 
error rate of 0.35%. Three errors were made in the gestational age at birth category, 4 in the birth 
weight category, 0 in the feeding category, 20 on infant factors, and 23 on maternal factors. 
Thirty-three of 49 (67.3%) nurses made no errors, and error rate was inversely related to the 
number of tools a given nurse scored (R2 = 0.53, P = 0.01).  
Cronbach’s alpha for variable categories included in the tool was 0.71. Removing the 
feeding category would increase Cronbach’s alpha to 0.82 and removing the infant factor 
category would slightly increase alpha to 0.73, while removal of any of the other variable 
categories would decrease alpha (Table 6.3). 
 
 Inter-rater reliability 
 The ICC was 0.99, indicating excellent consistency between nurses. Fleiss’ kappa was 
1.00, indicating that risk categorization determination (high, moderate, or low) was consistent 
even when total score disagreement was present.   
 
154 
 
 Identification of significant risk factors 
 The following risk factors were identified by chi-square testing to be significant (P < 
0.05) to the development of all four outcome measures: gestational age at birth, 
hypoxia/asphyxia at birth, RBC transfusion, and congenital heart disease/patent ductus arteriosis 
(Table 6.4). In addition, birth weight, feeding, and respiratory distress were significant to the 
number of days with emesis. Birth weight, incomplete or no antenatal steroids, respiratory 
distress, antibiotics ≥ 5 days, and sepsis were significant to days with abdominal distention. Birth 
weight was significant to number of days with gastric residuals > 50% of previous feeding 
volume, and maternal cigarette use, antibiotics ≥ 5 days, and sepsis were significant to NEC 
development.  
 
 Predictive validity 
 Area under the ROC curve (AUC) as well as diagnostic OR estimates and 95% CI for the 
number of days with emesis (AUC = 0.71; OR = 1.14 [1.07, 1.23]), abdominal distention (AUC 
= 0.81; OR = 1.27 [1.17, 1.40]), or gastric residuals > 50% of previous feeding volume (AUC = 
0.63; OR = 1.09 [1.03, 1.16]) and NEC (AUC = 0.94; OR = 1.45 [1.20, 1.91]), demonstrated 
total tool score to be associated with all 4 of the outcomes measures. (Figure 6.2).  
 
 Construct validity and comparison with GutCheckNEC 
 Pearson correlation coefficient for the two tools was 0.80 (P < 0.001), indicating strong 
correlation between the two scores of a given infant. The tools demonstrated similar correlation 
coefficients to one another for each of the four outcome measures (Table 6.5). Furthermore, 
independent t-test revealed significant differences in scores of infants who did and did not 
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develop each of the four outcome measures when both the tool presented here and the 
GutCheckNEC tool were used (Table 6.6).  
 
 Tool optimization 
 The following factors were not significantly associated with at least two of the three 
feeding intolerance outcomes, or with NEC, and were thus removed from the tool: feeding, 
polycythemia, IUGR or small for gestational age, placental abruption, clinical chorioamnionitis, 
maternal illicit drug use during pregnancy, preterm premature rupture of membranes, prolonged 
rupture of membranes, and absent or reversed end diastolic flow. Based on chi-square 
assessment of additional factors from the literature (Table 6.7), and following elimination of 
redundant variables, Apgar score at one minute and cesarean section delivery were added to the 
tool. The following pairs of factors were significantly correlated: 1) gestational age at birth and 
birth weight (P < 0.001); 2) respiratory distress and hypoxia (P < 0.001); 3) RBC transfusion and 
hypotension treated with inotropic medication (P < 0.01); and 4) sepsis and antibiotics ≥ 5 days 
(P = 0.001). The final version of the tool is show in Table 6.8. This optimized tool is greatly 
simplified, containing only 9 factors, with possible point totals ranging from 2 to 24.  
 In reassessing predictive validity, AUC as well as diagnostic OR estimates and 95% CI 
for the number of days with emesis (AUC = 0.69; OR = 1.14 [1.06, 1.23]), abdominal distention 
(AUC = 0.82; OR = 1.28 [1.18, 1.41]), or gastric residuals > 50% of previous feeding volume 
(AUC = 0.64; OR = 1.11 [1.04, 1.20]) and NEC (AUC = 0.90; OR = 1.29 [1.12, 1.56]), again 
demonstrated total tool score to be associated with all 4 of the outcomes measures. (Figure 6.3).  
 Pearson correlation coefficient for the optimized tool and GutCheckNEC improved slightly 
to 0.82 (P < 0.001), again indicating strong correlation between the two scores of a given infant. 
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Correlation coefficients for optimized total tool score and each of the three feeding intolerance 
outcomes improved versus the un-optimized tool (emesis, 0.51; abdominal distention, 0.61; 
gastric residuals > 50% previous feeding volume, 0.49), while that of NEC decreased slightly to 
0.35. Independent t-test again revealed significant differences in optimized tool score of infants 
who did and did not develop each of the four outcome measures (Figure 6.4). This allowed for 
identification of a single “at risk” threshold of ≥ 9 points, simplifying the risk categorization 
determination.  
 
DISCUSSION 
Results presented here demonstrate the clinical utility and predictive validity of this novel 
feeding intolerance and NEC risk scoring tool. In reinforcement of the pilot study results, the 
tool was assessed as easy to use and valued by nurses. The error rate remained similar to that in 
the pilot study, but with continued use, this error rate may decrease given that the study protocol 
nurse had an error rate of 7.1%. Cronbach’s alpha indicated the five categories of variables 
included in the tool all measure the same construct with reasonable clinical accuracy, and inter-
rater reliability was demonstrated to be excellent. Gestational age at birth, hypoxia/asphyxia at 
birth, RBC transfusion, and congenital heart disease/patent ductus arteriosis were identified as 
significant to the development of all four risk factors. The AUC, or probability that a randomly 
chosen infant who developed a given outcome scored higher than a randomly chosen infant who 
did not develop the given outcome,28 was most discriminatory for abdominal distention and 
NEC. The diagnostic OR (and 95% CI) was > 1 for all 4 outcome measures, and scores of infants 
who did and did not develop each of the 4 outcome measures were significantly different from 
one another using both the optimized tool and GutCheckNEC. The tool was demonstrated to be 
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similar to GutCheckNEC, despite inclusion of overlapping, but also unique, risk factors. Finally, 
given that maternal factors were the greatest source of error and nurse confusion prior to 
optimization, it is likely that the ease of use of the tool will be increased, and its estimated 
completion time decreased, though this optimization.  
 In considering similarities and differences between the two tools, it is important to note 
that GutCheckNEC was designed to be predictive only of NEC, not of other indices of feeding 
intolerance. Furthermore, GutCheckNEC was developed via modeling only for use in very low 
birth weight (VLBW) infants, and the feasibility of nursing use of GutCheckNEC has yet to be 
evaluated. It is also unclear at what point in an infant’s clinical care GutCheckNEC is designed to 
be used. Inclusion of a feeding risk factor which requires information on what the infant is fed on 
both days 7 and 14 of life indicate that GutCheckNEC is to be used after the 14th day of life. 
Waiting until the 14th day of life to assess risk NEC risk is justified as NEC is often not 
diagnosed until beyond day 14 of life.29 However, the tool presented here is designed to assess 
risk of both feeding intolerance and NEC, and is thus intended to be used at NICU admission and 
weekly until discharge since early and often evaluation of risk will be crucial for prevention of 
disease progression. Here, 85.7% of surveyed nurses stated they would be willing to use the tool 
at least daily for an infant under their care, indicating that weekly scoring would be supported. 
Unit NEC rate carries the most weight in the summed GutCheckNEC score, and can 
potentially be used as a proxy to represent multiple institutional practices that impact NEC risk.1 
The study site NEC rate was 2.0 ± 0.1% among VLBW infants in 2014, which may be reflective 
of strict use of standardized feeding protocols and prioritization of human milk feeding. While 
this low study site NEC rate is a boon for infants, caution must be exercised in interpreting tool 
NEC predictive validity as only 6 cases of NEC presented in enrolled infants. However, the 
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diagnostic OR is independent of outcome prevalence, so reasonable confidence in the ability of 
the tool to predict NEC risk is warranted.  
Following presentation of the tool at the 2013 National Association of Neonatal Nurses 
(NANN) conference, multiple attendees expressed interest in implementing the tool at their 
home institutions (Chapter 5). However, before doing so, it is important to consider how the 
tool’s predictive validity might differ if used in an institution that does not use standardized 
feeding protocols, has a NEC rate very different from the study site, or utilizes probiotics. It must 
also be noted that tool performance (for example, AUC) may change when the tool is applied in 
different clinical situations or populations, and that the most robust validation of the tool would 
be achieved through a pooled analysis of prospective studies at multiple study sites.30 Such an 
analysis may also serve to further refine the factors included in the tool. In its current form, the 
tool may be used to raise nursing awareness of the factors that contribute to preterm infant 
feeding intolerance and NEC risk. Additional refinement should further improve its clinical 
utility, ensure broad applicability, and justify individualized infant care according to risk 
categorization.  
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FIGURES AND TABLES 
 
 
Points Variable Category and Risk Factors 
Gestational Age at Birth (select one) 
1 32 - 36 6/7 weeks  
2 28 - 31 6/7 weeks   
3 < 28 weeks    
Birth Weight (select one) 
0 ≥ 2500 g 
1 1500 - 2499 g (low birth weight) 
2 1000 - 1499 g (very low birth weight)                
3 < 1000 g (extremely low birth weight)       
Feeding Substance (select all that apply) 
0 Mother’s own milk 
1 Donor breast milk; nil per os (NPO); total parenteral nutrition (TPN)                            
2 Bovine human milk fortifier 
3 Bovine-based formula           
Infant Risk Factors (select all that apply) 
1 Congenital heart disease or patent ductus arteriosis 
2 Red blood cell transfusion 
2 Polycythemia (hematocrit > 60) 
2 Respiratory distress (> 24 hours assisted ventilation)  
3 Hypoxia/asphyxia at birth 
3 Sepsis 
3 Antibiotics for ≥ 5 days 
3 Intrauterine growth restriction or small for gestational age 
Maternal Factors (select all that apply) 
1 Cigarette use during pregnancy                                                                   
2 Placenta abruption                                                                                           
2 Clinical chorioamnionitis  
2 Illicit drug use during pregnancy                                                                                            
2 Preterm premature rupture of membranes  
2 Prolonged rupture of membranes  (≥ 18 hours)    
3 Incomplete or no antenatal glucocorticoid therapy  
3 Absent or reversed end diastolic flow to infant  
 
Table 6.1. Revised feeding intolerance and necrotizing enterocolitis risk scoring tool.(Chapter 5) 
Scoring risk ranges: 1-5, low; 6-8, moderate; ≥ 9, high. 
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Figure 6.1. Infant demographics. A) Birth weight and gestational age at birth of enrolled infants. 
Birth weight categories: extremely low, < 1000 g; very low, < 1500 g; low, < 2500 g; normal, ≥ 
2500 g. B) Gender and single versus multiple gestation of enrolled infants.   
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Survey Question 
(n = 42) 
Response 
Comments (n) 
n % 
Estimate the number of times you have used the tool. 
 1-5 7 16.7  
 6-10 12 28.6  
 11-15 6 14.3  
 > 15 17 40.5  
Rank the ease of use of the tool.  
 1 (very difficult) 0 0  
 2 0 0  
 3 2 4.8 Difficult to identify/correct previous errors (1)  
 4 4 9.5 Info not always available or is difficult to find (2)  
 5 3 7.1 Can be difficult to find maternal factors (1)  
 6 7 16.7 
Can be difficult to find historical information (1)  
Require more formal tool education (1) 
 7 8 19 Can be difficult to find maternal factors (1)  
 8 11 26.2 Can be difficult/take time to find maternal factors (2)  
 9 3 7.1 Can be difficult to find historical information (2)  
 10 (very easy) 4 9.5 Quick, effective (1)  
 Mean (SD) 6.9 (1.9)  
Estimate the number of minutes the tool requires to complete, on average. 
 Mean (range) 4.2 (1-10)  
Has the tool raised your awareness of risk factors that contribute to feeding intolerance and NEC? 
 Yes 41 97.6  
 No 1 2.4  
Does the tool address important gaps in knowledge in the area of feeding intolerance within the NICU? 
 Yes 39 92.9  
 No 3 7.1  
Does knowing a baby's risk provide you with better information to care for the baby? 
 Yes 34 81.0  
     
 No 8 19.0 
Care dependent on provider (1) 
Already on high alert for signs of NEC regardless of score (3) 
How often would you be willing to utilize the tool for an infant under your care? 
 Every shift 25 59.5 Increases awareness for potential complications (1)  
 Daily 11 26.2  
 Weekly 5 11.9 Less frequent OK for infants on regular feedings (1)  
 Monthly 1 2.4  
Was the training you received regarding tool use adequate? 
 Yes 34 81.0  
     
 
No 8 19.0 
Need clarification on a particular item (6) 
Was unable to attend trainings (1) 
Could improvements be made to the tool to make it easier to use? 
 
Yes 32 76.2 
Mother’s information not consistently available in infant’s chart (5)  
Need clarification on particular item (1) 
Location of tool in chart (1)  
Need more practice using the tool (1) 
     
 No 10 23.8 Easy and comprehensive (1) 
 
Table 6.2. Study site survey results. Abbreviations: NEC, necrotizing enterocolitis.  
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Deleted variable category Cronbach’s alpha 
    Gestational age at birth 0.62 
    Birth weight 0.62 
    Feeding 0.82 
    Infant factors 0.73 
    Maternal factors 0.63 
 
Table 6.3. Scoring consistency of tool variable categories as assessed by Cronbach’s alpha. 
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 Outcomes 
Variable included in tool Emesis1 
Abdominal 
distention1 
Gastric 
residuals1,2 
NEC3 
*Gestational age at birth < 0.001 < 0.001 0.01 0.03 
Birth weight < 0.001 < 0.001 < 0.001 0.14 
Feeding 0.03 0.48 0.09 0.75 
Infant risk factors 
*Congenital heart disease/patent ductus arteriosis 0.01 < 0.001 < 0.001 0.01 
*Red blood cell transfusion < 0.001 < 0.001 < 0.001 < 0.001 
Polycythemia (hematocrit > 60) 0.996 0.21 0.83 0.5 
Respiratory distress (> 24hr assisted ventilation)  < 0.001 0.001 0.09 0.09 
*Hypoxia/asphyxia at birth 0.04 < 0.001 0.04 0.002 
Sepsis 0.69 < 0.001 0.33 < 0.001 
Antibiotics ≥ 5 days 0.07 < 0.001 0.051 < 0.001 
IUGR or small for gestational age 0.25 0.83 0.41 0.45 
Maternal factors 
Cigarette use during pregnancy                                                                   0.58 0.29 0.27 0.008 
Placenta abruption                                                                                           0.57 0.62 0.98 0.38 
Clinical chorioamnionitis  0.16 0.21 0.72 0.32 
Illicit drug use during pregnancy                                                                                            0.61 0.19 0.68 0.38 
Preterm premature rupture of membranes  0.0497 0.19 0.58 0.99 
Prolonged rupture of membranes  (≥ 18 hr)    0.6 0.12 0.54 0.72 
Incomplete/no antenatal glucocorticoid therapy  0.005 0.03 0.1 0.64 
Absent or reversed end diastolic flow  0.93 0.98 0.42 0.62 
 
Table 6.4. Chi-square test of association between risk factors and outcome measures. 
*Significant to the development of all 4 outcome measures.  
1Number of days during neonatal intensive care unit stay the outcome occurred.  
2Gastric residuals > 50% of previous feeding volume.  
3Diagnosis of necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 777.52, or 
777.53.  
Abbreviations: hr, hours; IUGR, intrauterine growth restriction; NEC, necrotizing enterocolitis.  
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Figure 6.2. Assessment of tool discrimination using receiver operating characteristic (ROC) 
curves for (A) emesis; (B) abdominal distention; (C) gastric residuals > 50% previous feeding 
volume; and (D) necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 777.52, 
or 777.53.  
  
  
A B 
C D 
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Outcome Tool GutCheckNEC 
Emesis days 0.46 0.49 
Abdominal distention days 0.57 0.65 
Gastric residual days1 0.41 0.39 
NEC2 0.38 0.40 
 
Table 6.5. Pearson correlation coefficient of total tool and GutCheckNEC scores with each of the 
four outcome measures.  
1Gastric residuals > 50% of feeding volume.  
2Diagnosis of necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 777.52, or 
777.53. 
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  Developed outcome Did not develop outcome 
P-value 
  Mean 95% CL SD Mean 95% CL SD 
Emesis
1
 
Tool 13.69 12.23, 15.16 6.24 9.39 8.13, 10.66 4.95 <0.001 
GutCheckNEC 17.04 15.15, 18.93 8.04 12.16 10.68, 13.65 5.81 <0.001 
Abdominal 
distention
1
 
Tool 15.85 14.17, 17.53 6.03 9.07 8.11, 10.04 4.38 <0.001 
GutCheckNEC 19.56 17.13, 21.99 8.72 11.75 10.77, 12.74 4.45 <0.001 
Gastric 
residuals
1,2
 
Tool 13.11 11.52, 14.71 6.67 10.17 8.94, 11.41 4.89 0.005 
GutCheckNEC 16.54 14.42, 18.67 8.91 12.87 11.64, 14.10 4.88 0.004 
NEC
3
 
Tool 22.33 18.31, 26.35 3.83 11.22 10.22, 12.22 5.68 <0.001 
GutCheckNEC 28.67 20.91, 36.43 7.39 14.15 12.95, 15.35 6.85 0.005 
 
Table 6.6. Comparison of scores of infants who did and did not develop feeding intolerance and 
NEC outcomes using an independent t-test of both the tool and GutCheckNEC.  
1Number of days during neonatal intensive care unit stay the outcome occurred.  
2Gastric residuals > 50% of feeding volume.  
3Diagnosis of necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 777.52, or 
777.53. 
 Abbreviations: CL, confidence limit; NEC, necrotizing enterocolitis; SD, standard deviation. 
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 Outcome 
Variable Emesis1 
Abdominal 
distention1 
Gastric 
residuals1,2 
NEC3 
Gender (male vs. female) 0.27 0.92 0.34 0.66 
*Delivery mode (vaginal vs. cesarean section) 0.02 0.01 0.07 0.97 
Ethnicity  0.39 0.20 0.10 0.76 
^Race (Black or Hispanic vs. all other races) 0.97 0.21 0.77 0.06 
Multiple gestation (singleton vs. multiple) 0.11 0.39 0.47 0.08 
^Birth site (outborn vs. inborn) 0.53 0.81 0.73 0.23 
*Apgar at 1 minute < 5 0.04 0.006 0.44 0.95 
Apgar at 5 minutes < 7 0.07 0.28 0.03 0.70 
Maternal hypertension during pregnancy 0.81 0.85 0.48 0.34 
Placental abnormality 0.68 0.48 0.87 0.37 
^Culture-proven infection since day 3 of life 0.69 < 0.001 0.33 < 0.001 
^Hypotension treated with inotropic medication 0.39 0.002 0.23 0.02 
^Metabolic acidosis 0.047 < 0.001 0.13 0.01 
 
Table 6.7. Assessment of additional factors for inclusion in the scoring tool.  
*Included in optimized tool.  
^Included in GutCheckNEC.  
1Number of days during neonatal intensive care unit stay the outcome occurred.  
2Gastric residuals > 50% of previous feeding volume.  
3Diagnosis of necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 777.52, or 
777.53.   
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Points Variable Category and Risk Factors 
Gestational Age at Birth (select one) 
2 32 - 36 6/7 weeks  
3 28 - 31 6/7 weeks   
4 < 28 weeks    
Infant Risk Factors (select all that apply) 
2 Apgar at 1 minute < 5 
2 Antibiotics for ≥ 5 days 
4 Congenital heart disease or patent ductus arteriosis 
4 Red blood cell transfusion 
4 Hypoxia/asphyxia at birth 
Maternal Factors (select all that apply) 
1 Cigarette use during pregnancy                                                                   
2 Incomplete or no antenatal glucocorticoid therapy  
3 Delivered via cesarean section  
 
Table 6.8. Optimized tool. An infant is determined to be at risk of feeding intolerance and/or 
NEC when the summed point total is ≥ 9.   
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Figure 6.3. Assessment of optimized tool discrimination using receiver operating characteristic 
(ROC) curves for (A) emesis; (B) abdominal distention; (C) gastric residuals > 50% previous 
feeding volume; and (D) necrotizing enterocolitis (NEC) per ICD-9 codes 557.0, 777.50, 777.51, 
777.52, or 777.53. 
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Figure 6.4. Comparison of scores of infants who did and did not develop feeding intolerance and 
NEC outcomes using an independent t-test.  
Data displayed as mean ± SEM.  
*Significant (P < 0.05) difference between mean total optimized tool score in infants who did 
and did not develop a given outcome.  
1Number of days during neonatal intensive care unit stay the outcome occurred.  
2Gastric residuals > 50% of previous feeding volume.  
Abbreviations: NEC, necrotizing enterocolitis.  
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CHAPTER 7 
SUMMARY AND FUTURE DIRECTIONS 
 
 
SUMMARY 
 Due to the immaturity of the gastrointestinal tract, preterm infants are at increased risk of 
feeding intolerance and NEC. If these conditions cannot be prevented and intestinal failure 
ensues, an infant may require long-term parenteral nutrition (PN) in order to support growth as 
well as maintain hydration and micronutrient status.1 Despite the life-saving nature of PN, it is 
also associated with numerous complications that are especially dangerous to infants.2-4 Thus, in 
order to prevent dependence on PN as well promote weaning when PN is required, the goal of 
treatment for these patients is to stimulate intestinal adaptation and achieve enteral autonomy.5 
To achieve this goal, it is crucial that the intestine undergo structural and functional adaptations 
to increase digestive and absorptive capabilities to a level which will be able to support infant 
growth.   
 Teduglutide reduces PN requirements in PN-dependent adults but is not approved for use 
in infants. Partial enteral nutrition (PEN) has been repeatedly demonstrated in both animal and 
human trials to prevent mucosal atrophy and promote intestinal adaptation. Furthermore, there is 
wide agreement that prediction and prevention of feeding intolerance and NEC will be the most 
efficacious means to improve infant outcomes related to feeding.6,7 
 Given the above, the specific aims of this research were to (1) assess the efficacy and 
safety of teduglutide in reducing PN (parenteral nutrient and/or fluid) requirements in PN-
dependent adults; (2) assess the efficacy of teduglutide and/or PEN in inducing intestinal 
adaptation in a neonatal piglet model of short bowel syndrome (SBS); and (3) develop and 
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validate a novel preterm infant feeding intolerance and NEC risk scoring tool to identify infants 
who may benefit from prophylactic or therapeutic teduglutide and/or PEN treatment. 
  
Hypothesis 1 
 In a systematic review of the literature, teduglutide treatment would decrease PN 
requirements of PN-dependent adults compared to placebo and demonstrate an acceptable safety 
profile. 
 Both efficacy (Table 3.2) and safety (Table 3.3) of teduglutide were demonstrated in the 
14 studies included in the systematic review, with number needed to treat to benefit (NNTB) 
ranging from 3 to 4, and the number needed to treat to harm (NNTH) ranging from 24 to 187. 
Thus, far more patients would need to be treated with teduglutide to cause harm to one additional 
patient than would need to be treated for one additional patient to benefit from treatment. This 
review was important to perform since duplicate publication, particularly with multiple meeting 
abstracts, appeared to artificially inflate the effects of teduglutide. 
 The distillation of data to original results presented here clearly describes both the 
benefits and risks of teduglutide treatment in adults, and provides preliminary data for 
consideration of its use in the pediatric population. Teduglutide is now available for prescription 
outside of clinical trials, but is mandated to participate in the United States Food and Drug 
Administration’s (FDA) Risk Evaluation & Mitigation Strategies (REMS) program. Rationale 
for requirement of REMS participation stems from the risks of gastrointestinal obstruction, 
biliary and pancreatic disorders, and acceleration of neoplastic or colon polyp growth associated 
with teduglutide use. Long-term data on the safety of teduglutide in adults has only yet been 
carried out for approximately three years, and caution must be exercised when considering 
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prescription of teduglutide in the more vulnerable pediatric population. Regardless of patient age, 
both benefits and risks of teduglutide treatment must be carefully considered on an individual 
patient basis before beginning treatment.   
  
Hypothesis 2 
 Teduglutide will enhance structural and functional adaptation of the residual small 
intestine via enhanced mucosal surface area and nutrient processing capacity in a neonatal piglet 
model of SBS, and these effects would be augmented by the provision of PEN. Furthermore, 
mucosal surface area expansion will precede functional adaptation. 
 In agreement with a previous piglet study,8 teduglutide enhanced structural, and 
transiently increased functional, measures of intestinal adaptation. Indices of intestinal adaptation 
stimulated by teduglutide and/or PEN were similar to those observed in preclinical GLP-2 and 
adult human teduglutide studies.9-14 Furthermore, complimentary roles for teduglutide and PEN 
were demonstrated in anatomical site and timing of action and structural versus functional 
measures of adaptation. Synergistic effects included, most notably, villus height of all intestinal 
segments and crypt depth of the jejunum, ileum, and colon.  
 The lack of lasting effect of teduglutide on functional indices of adaptation in this study 
and others8 may be due to the dosing strategies used in either piglet study, thus further work on 
optimal pediatric dosing needs to be completed. Additionally, as noted above, data on long-term 
safety of teduglutide in adults may also serve to inform optimal pediatric dosing, once that data 
is available. Nonetheless, coupling teduglutide and PEN therapies represents an opportunity to 
augment intestinal adaptation in neonatal SBS beyond that of either therapy alone, and 
potentially accelerate enteral autonomy in this population.    
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 Hypothesis 3 
 Accurate prediction of infant feeding intolerance and NEC risk can be accomplished by 
comprehensive assessment of feeding practices as well as relevant infant and maternal factors. 
Furthermore, a novel risk scoring tool will be easy to use since similarly designed tools have 
been successful in predicting and reducing the incidence of falls in the elderly15 and pressure 
ulcers in adults.16 
Following pilot testing, the tool was demonstrated to be simple to use and valued by 
nurses. Its accuracy, consistency, inter-rater reliability, and predictive validity were in acceptable 
ranges. Clinical testing revealed clear modifications that could be made to the tool to improve its 
clinical utility, which were implemented during optimization of the tool.  
 Though the tool could likely be improved through implementation at additional 
institutions and subsequent further refinement, in its current form, the tool is instrumental in 
raising awareness of the factors that contribute to feeding intolerance and NEC, helping nurses to 
put disparate clinical signs into context, and communicating risk of these conditions to providers. 
Though some factors of feeding intolerance and NEC development are unmodifiable (gestational 
age at birth, for example), nursing focus should be on those that can be modified through 
alteration of clinical practice. Of particular importance as indicated by the tool, are ensuring that 
all infants receive a complete course of antenatal glucocorticoid therapy, and preventing sepsis 
and hypoxia.  
Even as research in this area advances, nurses will remain critical first-line defenders in 
detection of feeding intolerance and NEC and important advocates for their patients. Providing 
nurses with an objective means with which to communicate risk of feeding intolerance and NEC 
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should improve the likelihood that their observations will be taken into consideration by NICU 
providers. 
 
FUTURE DIRECTIONS 
 The tool could be further improved by following up on interest already expressed by 
other institutions to strengthen the validity of the tool to ensure that it’s broadly applicable to 
infants on a larger scale. Specifically, implementing the tool at additional institutions would also 
allow for exploration of the possibility of including an institutional risk factor on the tool,17,18 
which may account for multiple risk factors, such as the use of standardized feeding protocols19-
25 and prioritization of human milk feeding,26 in a single variable, thus simplifying scoring.  
 The tool could also be used to justify research regarding investigation and application of 
new NEC treatments, including the use of teduglutide, according to NEC risk categorization. 
Additionally, the tool could be used to validate potential biomarkers of NEC such as urinary 
creatinine and fatty acid binding protein,27-29 or fecal calprotectin30 and volatile organic 
compounds.31,32 Such biomarkers have been previously proposed to be predictive of NEC onset 
or severity, but being able to correlate biomarker levels with infant NEC risk and subsequent 
outcome could further justify the use of such markers. Additional emerging techniques and 
biomarkers such as the use of proteomics33 may also serve as means to assess infant feeding 
intolerance and NEC risk. Though not all of these biomarkers could be evaluated by the bedside 
nurse, combining them with the tool may maximize clinical NEC predictive capabilities. The 
future directions outlined here will be important in ensuring a broadly applicable risk scoring 
tool that will maximally improve both short- and long-term preterm infant outcomes for minimal 
time and financial cost. 
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CONCLUSION 
 This work established a novel tool to assess preterm infant feeding intolerance and NEC 
risk though evaluation of relevant infant and maternal factors. Though it will continue to be 
refined, it also lays the groundwork for identification of infants who may benefit from 
prophylactic therapies in order to promote gastrointestinal maturation in an effort to prevent 
feeding intolerance. In addition, this work also establishes teduglutide, already approved for use 
in PN-dependent adults, as a potential means by which to promote enteral autonomy in the 
pediatric population, specifically through promotion of primarily structural, but to a lesser degree 
functional, measures of intestinal adaptation. The data presented here furthers knowledge in the 
area of preterm infant feeding intolerance and identifies future directions for this line of research.   
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